Document:

exv10w13

 

Exhibit 10.13

UMass Agreement No. UMMC 03-33-06

LICENSE AGREEMENT

     This Agreement, effective as of May 18, 2006 (the “Effective Date”), is between the University
of Massachusetts Medical School (“Medical School”), a public institution of higher education of the
Commonwealth of Massachusetts having an address of 333 South Street, Suite 400, Shrewsbury, MA
01545, and CytRx Corporation (“Company”), a Delaware corporation having an address of 11726 San
Vicente Blvd., Suite 650, Los Angeles, CA 90049.

R E
C I T A L S

     WHEREAS, Medical School is owner by assignment of the invention claimed in the United States
Patent Application listed in Exhibit A pertaining to the Medical School’s invention disclosures
numbers UMMC 03-33, 03-61, and 03-101; and

     WHEREAS, Medical School has exclusively licensed the invention to Sirna Therapeutics, Inc.
with a reservation that allows the Medical School to grant this license to Company concurrently in
certain limited fields; and

     WHEREAS, Company desires to obtain a license to the above referenced invention for certain
limited fields pertaining to the development of prophylactics, therapeutics, and diagnostics for
diabetes, obesity, Amyotrophic Lateral Sclerosis (ALS), and human cytomegalovirus (HCMV) under the
rights of Medical School in any patent rights claiming those inventions; and

     WHEREAS, Medical School is willing to grant Company a license on the terms set forth in this
Agreement; and

     WHEREAS, Company and Sirna Therapeutics, Inc. are the only licensees of the technology;

     THEREFORE, Medical School and Company hereby agree as follows: 1.

Definitions.

     1.1. “Affiliate” means any legal entity (such as, a corporation, partnership, or
limited liability company) that is controlled by Company. For the purposes of this
definition, the term “control” means (a) beneficial ownership of at least fifty percent (50%)
of the voting securities of a corporation or other business organization with voting
securities or (b) a fifty percent (50%) or greater interest in the net assets or profits of a
partnership or other business organization without voting securities.

     1.2. “Collaborator” means a commercial entity that enters into a written agreement
for a corporate partnership, joint venture, or other strategic alliance with Company or its
Affiliate for research, development, and/or commercialization of one or more Licensed
Products.

[***] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with the Commission.

Page 1 of 20

 

UMass Agreement No. UMMC 03-33-06

     1.3. “Confidential Information” means any confidential or proprietary information
furnished by one party (the “Disclosing Party”) to the other party (the “Receiving Party”) in
connection with this Agreement, provided that such information is specifically designated
as confidential. Such Confidential Information includes, without limitation, any diligence
reports furnished to Medical School under Section 3.1. and royalty reports furnished to
Medical School under Section 5.2.

     1.4. “Field” means therapeutics, prophylactics and diagnostics arising from the use
of RNAi to (a) inhibit human cytomegalovirus Immediate Early (IE) gene expression, (b)
inhibit mutant SOD1 gene expression in amyotrophic lateral sclerosis (ALS) applications,
and (c) inhibit gene targets implicated in type II diabetes and obesity.

     1.5. “Licensed Product” means any product that cannot be developed,
manufactured, used, or sold without (a) infringing one or more Valid Claims under the
Patent Rights, or (b) using some portion of the Related Technology.

     1.6.“Net Sales” means the gross amount billed or invoiced on sales by Company
and its Affiliates and Sublicensees of Licensed Products, less the following: (a) customary
trade, quantity, or cash discounts and commissions to non-affiliated brokers or agents to
the extent actually allowed and taken; (b) amounts repaid or credited by reason of rejection
or return; (c) outbound transportation costs prepaid or allowed and costs of insurance in
transit; (d) any taxes or other governmental charges levied on the production, sale,
transportation, delivery, or use of a Licensed Product which is paid by or on behalf of
Company, all to the extent separately stated on purchase orders, invoices, or other
documents of sale.

     In any transfers of Licensed Products between Company and an Affiliate or Sublicensee, Net
Sales shall be calculated based on the final sale of the Licensed Product to an independent third
party. In the event that Company or an Affiliate or Sublicensee receives non-monetary consideration
for any Licensed Products, Net Sales shall be calculated based on the fair market value of such
consideration.

1.7. “Other Company Technology” means any technology other than the Patent
Rights that is developed by Company or is licensed by Company from Medical School.

     1.8. “Patent Rights” means (a) the provisional and non-provisional United States
patent and foreign patent applications listed on Exhibit A, (b) any divisional,
continuation,
continuation-in-part, substitution or addition of such patent applications to the extent the claims
are directed to subject matter specifically described therein as well as any patent issued thereon,
(c) and any renewals, reissues, reexaminations, substitutions or extensions thereof, including
supplementary protection certificates, and (d)all foreign counterparts to such patents and patent
applications.

Page 2 of 20

 

UMass Agreement No. UMMC 03-33-06

     1.9. “Related Technology” means any know-how, technical information, research
and development information, test results, and data necessary for the effective exercise of
the Patent Rights which have been developed by Dr. Tariq M. Rana and his associates in
his laboratory at the Medical School as of the Effective Date and which are owned by
Medical School.

     1.10. “Royalty Period” means the partial calendar quarter commencing on the date
on which the first Licensed Product is sold or used and every complete or partial calendar
quarter thereafter during which either (a) this Agreement remains in effect or (b) Company
has the right to complete and sell work-in-progress and inventory of Licensed Products
pursuant to Section 8.5.

     1.11.“Sublicense Income” means any payments that Company receives from a
Sublicensee in consideration of the sublicense of the rights granted Company under Section
2.1., including without limitation license fees, milestone payments, and license
maintenance fees, but excluding royalties

     1.12. “Sublicensee” means any permitted sublicensee of the rights granted
Company under this Agreement, as further described in Section 2.2.

     1.13. “Valid Claim” means (a) in the case of a United States or foreign patent
application, a claim that has not been cancelled, withdrawn, or abandoned without being
refiled in another application claiming priority from said patent application; or that has not
been finally rejected by an administrative agency action from which no appeal can be
taken; or (b) in the case of an unexpired United States or foreign patent (or either one of the
foregoing that has been granted patent term extension or its equivalent), a claim that has
not been donated to the public, withdrawn, canceled or disclaimed, or held invalid or
unenforceable by a court or government agency of competent jurisdiction in an unappealed
or unappealable decision, including, through opposition, reexamination, reissue or
disclaimer.

2. Grant of Rights.

     2.1. License Grants.

          (a) Patent Rights. Subject to the terms of this Agreement, Medical School
hereby grants to Company and its Affiliates a co-exclusive, worldwide, royalty-bearing
license (with a limited right to sublicense) under its commercial rights in the Patent Rights
to develop, make, have made, use, sell, and have sold Licensed Products in the Field.

          (b) Related Technology. Subject to the terms of this Agreement, Medical
School hereby grants to Company and its Affiliates a non-exclusive, royalty-bearing license
(with the right to sublicense) under its commercial rights in the Related Technology to
develop, make, have made, use, sell, and have sold Licensed Products in the Field.

Page 3 of 20

 

UMass Agreement No. UMMC 03-33-06

     2.2. Sublicenses. Company may grant sublicenses of its rights under Section 2.1
with the consent of Medical School, which consent may not be unreasonably withheld or
delayed, but only (a) when Company grants a license to Other Company Technology and
the sublicense is reasonably required to practice the Other Company Technology or (b)
when the sublicense is granted to Collaborators. All sublicense agreements executed by
Company pursuant to this Article 2 shall expressly bind the Sublicensee to the terms of this
Agreement, and Company shall promptly furnish Medical School with a fully executed
copy of the sublicense agreement.

     2.3. Retained Rights.

          (a) Medical School. Medical School retains the right to make and use
Licensed Products for academic research, teaching, and non-commercial patient care,
without payment of compensation to Company. Medical School may license its retained
rights under this Section to research collaborators of Medical School faculty members,
post-doctoral fellows, and students.

          (b) Federal Government. The invention claimed in the Patent Rights has
been partially funded by the federal government. Therefore, this Agreement and the grant
of any rights in such Patent Rights are subject to and governed by federal law as set forth in
35 U.S.C. §§ 201-211, and the regulations promulgated thereunder, as amended, or any
successor statutes or regulations. Company acknowledges that these statutes and
regulations reserve to the federal government a royalty-free, non-exclusive, non-
transferable license to practice any government-funded invention claimed in any Patent
Rights. If any term of this Agreement fails to conform with such laws and regulations, the
relevant term shall be deemed an invalid provision and modified in accordance with
SectionlO.il.

          (c) Other Organizations. To the extent that any invention claimed in the
Patent Rights has been partially funded by a non-profit organization or state or local
agency, this Agreement and the grant of any rights in such Patent Rights are subject to and
governed by the terms and conditions of the applicable research grant. If any term of this
Agreement fails to conform with such terms and conditions, the relevant term shall be
deemed an invalid provision and modified by the parties pursuant to Section 10.11. Upon
execution of this Agreement, the Medical School shall disclose in writing to Company any
funding that would be subject to this Section 2.3(c).

     2.4. Termination of Sirna Therapeutics, Inc. License. If the license for Patent
Rights with Sirna Therapeutics, Inc. is terminated, Medical School (a) may license the
Patent Rights outside of the Field to any other party and (b) for Patent Rights in the Field,
Medical School hereby grants Company a first option to obtain a worldwide, royalty
bearing exclusive license (the “Option Right”). Company may exercise the Option Right
by written notice to Medical School which is received by Medical School not later than
sixty (60) days after notification to Company of the termination of the Sirna Therapeutics,
Inc. license (which notification shall be delivered within a reasonable time to the
Company). If Company does not elect to exercise the Option Right, or fails to do so within

Page 4 of 20

 

UMass Agreement No. UMMC 03-33-06

the 60 day option period, Medical School may license its commercial rights under the Patent Rights
in the Field to any third party. If Company does exercise the Option Right, Medical School and
Company shall negotiate in good faith a license agreement containing commercially reasonable terms.
If Medical School and Company are unable to reach an agreement within three (3) months after
Company exercises the Option Right, Medical School may offer its commercial rights in the relevant
Patent Rights in the Field to any third parties.

3. Company Obligations Relating to Commercialization.

     3.1. Diligence Requirements. Company shall use diligent efforts, or shall cause its
Affiliates and Sublicensees to use diligent efforts, to develop Licensed Products and to introduce
Licensed Products into the commercial market place; thereafter, Company or its Affiliates or
Sublicensees shall make Licensed Products reasonably available to the public. Specifically, Company
or Affiliate or Sublicensee shall fulfill the following obligations:

     (a) Within ninety (90) days after the Effective Date, Company shall furnish
Medical School with a written research and development plan under which
Company intends to develop Licensed Products.

     (b) Within sixty (60) days after the start of each calendar year during the
term of this Agreement, Company shall furnish Medical School with a written
report on the progress of its efforts during the prior year to develop and
commercialize Licensed Products, including without limitation research and
development efforts, efforts to obtain regulatory approval, marketing efforts, and
sales figures. The report shall also contain a discussion of intended efforts and
sales projections for the current year.

     (c) Company shall obtain all necessary governmental approvals for the
manufacture, use, and sale of Licensed Products.

     (d) Within seven (7) years after the Effective Date, Company shall file an
Investigational New Drug Application (“IND”) or its equivalent covering at least
one Licensed Product with the United States Food and Drug Administration
(“FDA”).

     (e) Within ten (10) years after the Effective Date, Company shall file a New
Drug Application (“NDA”) with the FDA covering at least one Licensed Product.

     (f) Within eighteen (18) months after receiving FDA approval of the NDA
for a Licensed Product, Company shall market at least one Licensed Product in the
United States.

     (g) Following commencement of marketing of a Licensed Product at any
time during the exclusive period of this Agreement, Company shall reasonably fill
the market demand for any Licensed Product.

Page 5 of 20

 

UMass Agreement No. UMMC 03-33-06

Company has the responsibility to finance its obligations in this Section 3.1. In the event that
Medical School determines that Company (or an Affiliate or Sublicensee) has not fulfilled its
obligations under this Section 3.1., Medical School shall furnish Company with written notice of
such determination. Within sixty (60) days after receipt of such notice, Company shall either (i)
fulfill the relevant obligation or (ii) negotiate with Medical School a mutually acceptable
schedule of revised diligence obligations, failing which Medical School shall have the right,
immediately upon written notice to Company, to terminate this Agreement. The Medical School may not
unreasonably withhold acceptance of Company’s revised diligence obligations.

     3.2. Indemnification.

          (a) Indemnity. Company shall indemnify, defend, and hold harmless
Medical School and its trustees, officers, faculty, students, employees, and agents and their
respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage,
loss, or expense (including reasonable attorneys fees and expenses of litigation) incurred by
or imposed upon any of the Indemnitees in connection with any claims, suits, actions,
demands or judgments arising out of any theory of liability (including without limitation
actions in the form of tort, warranty, or strict liability and regardless of whether such action
has any factual basis) concerning any product, process, or service that is made, used, or
sold pursuant to any right or license granted under this Agreement; provided, however, that
such indemnification shall not apply to any liability, damage, loss, or expense to the extent
directly attributable to (i) the gross negligence or intentional misconduct of the Indemnitees
or (ii) the settlement of a claim, suit, action, or demand by Indemnitees without the prior
written approval of Company.

          (b) Procedures. The Indemnitees agree to provide Company with prompt
written notice of any claim, suit, action, demand, or judgment for which indemnification is
sought under this Agreement. Company agrees, at its own expense, to provide attorneys
reasonably acceptable to Medical School to defend against any such claim. The
Indemnitees shall cooperate fully with Company in such defense and will permit Company
to conduct and control such defense and the disposition of such claim, suit, or action
(including all decisions relative to litigation, appeal, and settlement); provided, however,
that any Indemnitee shall have the right to retain its own counsel, at the expense of
Company, if representation of such Indemnitee by the counsel retained by Company would
be inappropriate because of actual or potential differences in the interests of such
Indemnitee and any other party represented by such counsel. Company agrees to keep
Medical School informed of the progress in the defense and disposition of such claim and
to consult with Medical School with regard to any proposed settlement.

          (c) Insurance. Company shall maintain insurance that is reasonably
adequate to fulfill any potential obligation to the Indemnitees, but in any event not less than
one million dollars ($1,000,000) for injuries to any one person arising out of a single
occurrence and five million dollars ($5,000,000) for injuries to all persons arising out of a
single occurrence. Company shall provide Medical School, upon request, with written

Page 6 of 20

 

UMass Agreement No. UMMC 03-33-06

evidence of such insurance. Company shall continue to maintain such insurance after the expiration
or termination of this Agreement during any period in which Company or any Affiliate or Sublicensee
continues to make, use, or sell a product that was a Licensed Product under this Agreement for a
period of two (2) years.

     3.3. Use of Medical School Name. In accordance with
Section 7.3., Company and its Affiliates and Sublicensees shall not use the name “University of Massachusetts Medical School” or any variation of that name in connection with the marketing or sale of
any Licensed Products.

     3.4. Marking of Licensed Products. To the extent commercially feasible and
consistent with prevailing business practices, Company shall mark, and shall cause its
Affiliates and Sublicensees to mark, all Licensed Products that are manufactured or sold
under this Agreement with the number of each issued patent under the Patent Rights that
applies to such Licensed Product.

     3.5. Compliance with Law. Company shall comply with, and shall ensure that its
Affiliates and Sublicensees (to the extent commercially feasible) comply with, all local,
state, federal, and international laws and regulations relating to the development,
manufacture, use, and sale of Licensed Products. Company expressly agrees to comply
with the following:

     (a) Company or its Affiliates or Sublicensees shall obtain all necessary
approvals from the United States Food & Drug Administration and any similar
governmental authorities of any foreign jurisdiction in which Company or an
Affiliate or Sublicensee intends to make, use, or sell Licensed Products.

     (b) Company and its Affiliates and Sublicensees shall comply with all
United States laws and regulations controlling the export of certain commodities
and technical data, including without limitation all Export Administration
Regulations of the United States Department of Commerce. Among other things,
these laws and regulations prohibit, or require a license for, the export of certain
types of commodities and technical data to specified countries. Company hereby
gives written assurance that it will comply with, and will cause its Affiliates and
Sublicensees to comply with, all United States export control laws and regulations,
that it bears sole responsibility for any violation of such laws and regulations by
itself or its Affiliates or Sublicensees, and that it will indemnify, defend, and hold
Medical School harmless (in accordance with Section 3.2.) for the consequences of
any such violation.

     (c) To the extent that any invention claimed in the Patent Rights has been
partially funded by the United States government, and only to the extent required by
applicable laws and regulations, Company agrees that any Licensed Products used
or sold in the United States will be manufactured substantially in the United States
or its territories. Current law provides that if domestic manufacture is not

Page 7 of 20

 

UMass Agreement No. UMMC 03-33-06

commercially feasible under the circumstances, Medical School may seek a waiver of this
requirement from the relevant federal agency on behalf of Company.

4. Consideration for Grant of Rights.

     4.1. License Fee, hi partial consideration of the rights granted Company under this
Agreement, Company shall pay to Medical School within ten (10) days after the Effective
Date a license fee of (***). The license fee is noncancelable (even if Company terminates
pursuant to Section 8.3), nonrefundable and not creditable against any other payments due to
Medical School under this Agreement.

     4.2. Equity. In partial consideration of the license granted to Company under this
Agreement, before December 31, 2006, Company shall issue to Medical School (***) shares of
Common Stock of Company. Company shall file a registration statement covering the resale of the shares that are issued to the Medical School within one hundred and twenty days (120) days after
their issuance to Medical School and those shares shall then be unrestricted

     4.3. License Maintenance Fee. Beginning on the first anniversary of the Effective
Date, and on each anniversary of the Effective Date thereafter during the term of the
Agreement, Company shall pay to Medical School (***). This annual license maintenance fee is
nonrefundable and is not creditable against any other payments due to Medical School under this
Agreement.

     4.4. Milestone Payments. Company shall pay Medical School the following
milestone payments within thirty (30) days after the occurrence of each event:

	 	 	 
	Milestone Event	 	Payment
	Filing of IND or equivalent for each Licensed Product

	 	(***)
	Entry into Phase I Clinical trial or equivalent for each Licensed Product

	 	(***)
	Entry into Phase II clinical trial or equivalent for each Licensed Product

	 	(***)
	Entry into Phase HI clinical trial or equivalent for each Licensed Product

	 	(***)
	NDA submission or its equivalent for each Licensed Product

	 	(***)
	Commencement of product marketing in the United States

	 	(***)
	Commencement of product marketing in Europe

	 	(***)

These milestone payments are nonrefundable and are not creditable against any other payments
due to Medical School under this Agreement.

Page 8 of 20

 

UMass Agreement No. UMMC 03-33-06

     4.5. Royalties.

          (a) Base Royalty. In partial consideration of the rights granted Company under this
Agreement, Company shall pay to Medical School a royalty of (***) percent (***) of Net Sales of
Licensed Products by Company, its Affiliates and Sublicensees.

          (b) Services royalty. Company shall pay Medical School (***) percent (***) of Net Sales
of commercial clinical laboratory services by Company and its Affiliates.

     4.6. Minimum Royalty. Within sixty (60) days after the beginning of each calendar year
during the term of this Agreement, beginning January 1, 2012, Company shall pay to Medical School a
minimum royalty of (***).Company may credit the minimum royalty paid under this Subsection 4.7
against actual royalties due and payable for the same calendar year. Waiver of any minimum royalty
payment by Medical School shall not be construed as a waiver of any subsequent minimum royalty
payment. If Company fails to make any minimum royalty payment within the sixty-day period, such
failure shall constitute a material breach of its obligations under this Agreement, and Medical
School shall have the right to terminate this Agreement in accordance with Section 8.3.

     4.7. Sublicense Income. Company shall pay Medical School (***) of all Sublicense
Income. Such Sublicense Income amounts shall be due and payable within sixty (60) days after
Company receives the relevant payment from the Sublicensee.

     4.8. Third-Party Royalties. If Company is legally required to make royalty payments to
one or more third parties in order to make, use, or sell Licensed Products, Company may offset a
total of fifty percent (50%) of actual third-party payments against any royalty payments that are
due to Medical School in the same Royalty Period. However, the royalty payments under Sections
4.5., may never result in a royalty lower than (***) in any Royalty Period. In the event that
Company is legally required to make royalty payments to Medical School for a Licensed Product under
any other license agreement, as well as this Agreement, the total royalty due to Medical School may
never be more than (***). The amendments to Section 4.6 or 4.8 dated February 1, 2004, in the
license agreements between Company and Medical School for UMMC 01-36, UMMC 02-01, UMMC 03-05, UMMC
03-17, UMMC 03-36 and UMMC 03-60 specifically do not apply to this Agreement. Further, no other
credits of payments due to Medical School under any other license agreement between Company and
Medical School apply to this Agreement.

     4.9. 5. Royalty Reports; Payments; Records.

     5.1. First Sale. Company shall report to Medical School the date of first commercial
sale of each Licensed Product within thirty (30) days of occurrence in each country.

Page 9 of 20

 

 

UMass Agreement No. UMMC 03-33-06

     5.2. Reports and Payments. Within sixty (60) days after the conclusion of each Royalty
Period, Company shall deliver to Medical School a report containing the following information:

     (a) the number of Licensed Products sold to independent third parties in each country,
and the number of Licensed Products used by Company, its Affiliates and Sublicensees in
each country;

     (b) the gross sales price for each Licensed Product sold by Company, its Affiliates
and Sublicensees during the applicable Royalty Period in each country;

     (c) calculation of Net Sales for the applicable Royalty Period in each country,
including a listing of applicable deductions;

     (d) total royalty payable on Net Sales in United States dollars, together with the
exchange rates used for conversion; and

     (e) the portion of royalty-based Sublicense Income due to Medical School for the
applicable Royalty Period from each Sublicensee.

All such reports shall be considered Company Confidential Information. If no royalties are due to
Medical School for any Royalty Period, the report shall so state. Concurrent with this report,
Company shall remit to Medical School any payment due for the applicable Royalty Period.

     5.3. Payments in United States Dollars. All payments due under this Agreement shall be
payable in United States dollars. Conversion of foreign currency to United States dollars shall be
made at the conversion rate existing in the United States (as reported in the Wall Street Journal)
on the last working day of the calendar quarter preceding the applicable Royalty Period. Such
payments shall be without deduction of exchange, collection, or other charges.

     5.4. Payments in Other Currencies. If by law, regulation, or fiscal policy of a
particular country, conversion into United States dollars or transfer of funds of a convertible
currency to the United States is restricted or forbidden, Company shall give Medical School prompt
written notice of such restriction, which notice shall satisfy the sixty-day payment deadline
described in Section 5.2. Company shall pay any amounts due Medical School through whatever lawful
methods Medical School reasonably designates; provided, however, that if Medical School fails to
designate such payment method within thirty (30) days after Medical School is notified of the
restriction, Company may deposit such payment in local currency to the credit of Medical School in
a recognized banking institution selected by Company and identified by written notice to Medical
School, and such deposit shall fulfill all obligations of Company to Medical School with respect to
such payment.

Page 10 of 20

 

 

UMass Agreement No. UMMC 03-33-06

     5.5. Records. Company shall maintain, and shall cause its Affiliates and Sublicensees
to maintain, complete and accurate records of Licensed Products that are made, used, sold, or
performed under this Agreement and any amounts payable to Medical School in relation to such
Licensed Products, which records shall contain sufficient information to permit Medical School to
confirm the accuracy of any reports delivered to Medical School under Section 5.2. Company,
Affiliates and Sublicensees shall retain such records relating to a given Royalty Period for at
least three (3) years after the conclusion of that Royalty Period, during which time Medical School
shall have the right, at its expense, to cause its internal accountants or an independent,
certified public accountant to inspect such records during normal business hours for the sole
purpose of verifying any reports and payments delivered under this Agreement. Such accountant shall
not disclose to Medical School any information other than information relating to accuracy of
reports and payments delivered under this Agreement. The parties shall reconcile any underpayment
or overpayment within thirty (30) days after the accountant delivers the results of the audit. In
the event that any audit performed under this Section reveals an underpayment in excess of ten
percent (10%) in any Royalty Period, Company shall bear the full cost of such audit. Medical School
may exercise its rights under this Section only once every year for each of Company, its Affiliates
or Sublicensees and only with reasonable prior notice to Company, its Affiliates or Sublicensees.

     5.6. Late Payments. Any payments by Company that are not paid on or before the date
such payments are due under this Agreement shall bear interest, to the extent permitted by law, at
two percentage points above the Prime Rate of interest as reported in the Wall Street Journal on
the date payment is due, with interest calculated based on the number of days that payment is
delinquent.

     5.7. Method of Payment. All payments under this Agreement should be made in the name
of the “University of Massachusetts Medical School” and sent to the address identified in Section
10.10 below. Each payment should reference this Agreement and identify the obligation under this
Agreement that the payment satisfies.

     5.8. Withholding and Similar Taxes. Royalty payments and other payments due to Medical
School under this Agreement shall not be reduced by reason of any withholding or similar taxes
applicable to such payments to Medical School, which shall be paid by Company as required by
applicable law and reported by Company to the Medical School.

6. Patents and Infringement.

     6.1. Responsibility for Patent Rights. Medical School shall have responsibility and
sole discretion for the preparation, filing, prosecution, and maintenance of all Patent Rights.
Subject to Medical’s School obligations to Sirna Therapeutics, Inc. with respect to Patent Rights
and Section 6.5 below, Medical School will keep Company informed of the status, prosecution and
maintenance of the Patent Rights and will consider Company’s comments and requests with respect
thereto in good faith.

Page 11 of 20

 

 

UMass Agreement No. UMMC 03-33-06

     6.2. Acknowledgement of Sirna Therapeutics, Inc. License Agreement. Company
acknowledges that the Medical School’s license of the Patent Rights to Sirna Therapeutics, Inc.,
may require the modification or abandonment of claims in the Patent Rights to resolve possible
patent interferences between the Medical School and Sirna Therapeutics, Inc

     6.3. Notification of Infringement. Each party agrees to provide written notice to the
other party promptly after becoming aware of any infringement of the Patent Rights.

     6.4. Abandonment. Subject to any obligations to Sirna Therapeutics, Inc., if Medical
School desires to abandon any patent or patent application within the Patent Rights (other than as
a result of any patent interference, litigation, or settlement of a patent interference or
litigation), Medical School shall provide Company with reasonable prior written notice of the
intended abandonment or decline of responsibility, and, in that case, Company may, at its expense,
prepare, file and prosecute, and maintain the relevant Patent Rights in the name of and on behalf
of the Medical School.

     6.5. Payment of Expenses. Within thirty (30) days after Medical School invoices
Company, Company shall reimburse Medical School for all out-of-pocket patent expenses incurred
pursuant to notice and consultation provisions of Section 6.1.

7. Confidential Information; Publications;
Publicity.

     7.1. Confidential Information.

          (a) Designation. Confidential Information that is disclosed in writing shall be marked
with a legend indicating its confidential status (such as “Confidential” or “Proprietary”).
Confidential Information that is disclosed orally or visually shall be documented in a written
notice prepared by the Disclosing Party and delivered to the Receiving Party within thirty (30)
days of the date of disclosure; such notice shall summarize the Confidential Information disclosed
to the Receiving Party and reference the time and place of disclosure.

          (b) Obligations. For a period of five (5) years after disclosure of any portion of
Confidential Infonnation, the Receiving Party shall (i) maintain such Confidential Information in
strict confidence, except that the Receiving Party may disclose or permit the disclosure of any
Confidential Information to its directors, officers, employees, consultants, and advisors who are
obligated to maintain the confidential nature of such Confidential Information and who need to know
such Confidential Information for the purposes of this Agreement; (ii) use such Confidential
Information solely for the purposes of this Agreement; and (iii) allow its trustees or directors,
officers, employees, consultants, and advisors to reproduce the Confidential Information only to
the extent necessary for the purposes of this Agreement, with all such reproductions being
considered Confidential Information.

          (c) Exceptions. The obligations of the Receiving Party under Subsection 7.1.(b) above
shall not apply to the extent that the Receiving Party can demonstrate that

Page 12 of 20

 

 

UMass Agreement No. UMMC 03-33-06

certain Confidential Information (i) was in the public domain prior to the time of its disclosure
under this Agreement; (ii) entered the public domain after the time of its disclosure under this
Agreement through means other than an unauthorized disclosure resulting from an act or omission by
the Receiving Party; (iii) was independently developed or discovered by the Receiving Party without
use of the Confidential Information; (iv) is or was disclosed to the Receiving Party at any time,
whether prior to or after the time of its disclosure under this Agreement, by a third party having
no fiduciary relationship with the Disclosing Party and having no obligation of confidentiality
with respect to such Confidential Information; or (v) is required to be disclosed to comply with
applicable laws or regulations, or with a court or administrative order, provided that the
Disclosing Party receives reasonable prior written notice of such disclosure.

          (d) Ownership and Return. The Receiving Party acknowledges that the Disclosing Party
(or any third party entrusting its own information to the Disclosing Party) claims ownership of its
Confidential Information in the possession of the Receiving Party. Upon the expiration or
termination of this Agreement, and at the request of the Disclosing Party, the Receiving Party
shall return to the Disclosing Party all originals, copies, and summaries of documents, materials,
and other tangible manifestations of Confidential Information in the possession or control of the
Receiving Party, except that the Receiving Party may retain one copy of the Confidential
Information in the possession of its legal counsel solely for the purpose of monitoring its
obligations under this Agreement.

     7.2. Publications. Medical School and its employees will be free to publicly disclose
(through journals, lectures, or otherwise) the results of any research in the Field or relating to
the subject matter of the Patent Rights.

     7.3. Publicity Restrictions. Neither party may use the name of the other or any of its
respective trustees, officers, faculty, students, employees, or agents, or any adaptation of such
names, or any terms of this Agreement in any promotional material or other public announcement or
disclosure without the prior written consent of the other party. The foregoing notwithstanding:

          (a) Company shall have the right to disclose such information without the consent of Medical
School in any prospectus, offering memorandum, or other document or filing required by applicable
securities laws or other applicable law or regulation, provided that Company shall have given
Medical School at least ten (10) days (or such prior shorter period in order to enable Company to
make a timely announcement, while affording the Medical School the maximum feasible time to review
the announcement) prior written notice of the proposed text for the purpose of giving Medical
School the opportunity to comment on such text.

          (b) The Medical School may disclose that Company is a licensee of the Patent Rights.

Page 13 of 20

 

 

UMass Agreement No. UMMC 03-33-06

8. Term and Termination.

     8.1. Term. This Agreement shall commence on the Effective Date and shall remain in
effect until (a) the expiration of all issued patents within the Patent Rights or (b) for a period
often (10) years after the Effective Date if no such patents have issued within that ten-year
period, unless earlier terminated in accordance with the provisions of this Agreement.

     8.2. Termination for Default. In the event that either party commits a material breach
of its obligations under this Agreement and fails to cure that breach within sixty (60) days after
receiving written notice thereof, the other party may terminate this Agreement immediately upon
written notice to the party in breach. If the alleged breach involves nonpayment of any amounts due
University under this Agreement, Company has only one opportunity to cure a material breach for
which it receives notice as described above. Any subsequent material breach by Company will entitle
University to terminate this Agreement immediately upon written notice to Company, without the
sixty-day cure period. Company acknowledges and agrees that there is no cure period for any default
or failure to make payments of cash under Subsection 4.1 (“Subsection 4.1 Default”), or any default
or failure to provide equity as provided under Subsection 4.2 (“Subsection 4.2 Default”).

     8.3. Voluntary Termination. Company may terminate this Agreement for any reason upon
ninety (90) days’ prior written notice to Medical School. Medical School may terminate this
Agreement immediately upon written notice to Company upon the occurrence of either (a) a Subsection
4.1 Default or (b) a Subsection 4.2 Default as described in Subsection 8.2.

     8.4. Termination Fee. Upon termination of this Agreement (a) by Medical School
according to the provisions of Subsection 8.3(b) or (b) Company prior to fulfilling it’s
obligations to issue equity to Medical School as provided under Subsection 4.2, Company shall pay
Medical School a termination fee of Twenty Five Thousand Dollars ($25,000). This termination fee is
non-refundable and not creditable to other payments due to Medical School under this Agreement.

     8.5. Force Majeure. Neither party will be responsible for delays resulting from causes
beyond the reasonable control of such party, including without limitation fire, explosion, flood,
terrorism, war, strike, or riot, provided that the nonperforming party uses commercially reasonable
efforts to avoid or remove such causes of nonperformance and continues performance under this
Agreement with reasonable dispatch whenever such causes are removed.

     8.6. Effect of Termination. The following provisions shall survive the expiration or
termination of this Agreement: Articles 1, 5, and 9; Sections 3.2., 3.5. 4.1, 7.1., 7.3., 8.4.,
8.6., and 10.9. Upon the early termination of this Agreement, Company and its Affiliates and
Sublicensees may complete and sell any work-in-progress and inventory of Licensed

Page 14 of 20

 

 

UMass Agreement No. UMMC 03-33-06

Products that exist as of the effective date of termination, provided that (a) Company is current
in payment of all amounts due Medical School under this Agreement, (b) Company pays Medical School
the applicable royalty on such sales of Licensed Products in accordance with the terms and
conditions of this Agreement, and (c) Company and its Affiliates and Sublicensees shall complete
and sell all work-in-progress and inventory of Licensed Products within six (6) months after the
effective date of termination. 9. Dispute Resolution.

     9.1. Procedures Mandatory. The parties agree that any dispute arising out of or
relating to this Agreement shall be resolved solely by means of the procedures set forth in this
Article, and that such procedures constitute legally binding obligations that are an essential
provision of this Agreement; provided, however, that all procedures and deadlines specified in this
Article may be modified by written agreement of the parties. If either party fails to observe the
procedures of this Article, as modified by their written agreement, the other party may bring an
action for specific performance in any court of competent jurisdiction.

     9.2. Dispute Resolution Procedures.

          (a) Negotiation. In the event of any dispute arising out of or relating to this
Agreement, the affected party shall notify the other party, and the parties shall attempt in good
faith to resolve the matter within ten (10) days after the date of such notice (the “Notice Date”).
Any disputes not resolved by good faith discussions shall be referred to senior executives of each
party, who shall meet at a mutually acceptable time and location within thirty (30) days after the
Notice Date and attempt to negotiate a settlement.

          (b) Mediation. If the matter remains unresolved within sixty (60) days after the
Notice Date, or if the senior executives fail to meet within thirty (30) days after the Notice
Date, either party may initiate mediation upon written notice to the other party, whereupon both
parties shall be obligated to engage in a mediation proceeding under the then current Center for
Public Resources (“CPR”) Model Procedure for Mediation of Business Disputes, except that specific
provisions of this Section shall override inconsistent provisions of the CPR Model Procedure. The
mediator will be selected from the CPR Panels of Neutrals. If the parties cannot agree upon the
selection of a mediator within ninety (90) days after the Notice Date, then upon the request of
either party, the CPR shall appoint the mediator. The parties shall attempt to resolve the dispute
through mediation until one of the following occurs: (i) the parties reach a written settlement;
(ii) the mediator notifies the parties in writing that they have reached an impasse; (iii) the
parties agree in writing that they have reached an impasse; or (iv) the parties have not reached a
settlement within one hundred and twenty (120) days after the Notice Date.

          (c) Trial Without Jury. If the parties fail to resolve the dispute through mediation,
or if neither party elects to initiate mediation, each party shall have the right to pursue any
other remedies legally available to resolve the dispute, provided, however, that the parties
expressly waive any right to a jury trial in any legal proceeding under this Section.

Page 15 of 20

 

 

UMass Agreement No. UMMC 03-33-06

     9.3. Preservation of Rights Pending Resolution.

          (a) Performance to Continue. Each party shall continue to perform its obligations
under this Agreement pending final resolution of any dispute arising out or relating to this
Agreement; provided, however, that a party may suspend performance of its obligations during any
period in which the other party fails or refuses to perform its obligations.

     (b) Provisional Remedies. Although the procedures specified in this Article
are the sole and exclusive procedures for the resolution of disputes arising out of
relating to this Agreement, either party may seek a preliminary injunction or other
provisional equitable relief if, in its reasonable judgment, such action is necessary to
avoid irreparable harm to itself or to preserve its rights under this Agreement.

     (c) Statute of Limitations. The parties agree that all applicable statutes of
limitation and time-based defenses (such as estoppel and laches) shall be tolled while the
procedures set forth in Subsections 9.2.(a) and 9.2(b) are pending. The parties shall take
any actions necessary to effectuate this result.

10. Miscellaneous.

     10.1. Representations and Warranties. Medical School represents and warrants that its
employees have assigned to Medical School their entire right, title, and interest in the Patent
Rights, and that it has authority to grant the rights and licenses set forth in this Agreement.
MEDICAL SCHOOL MAKES NO OTHER WARRANTIES CONCERNING THE PATENT RIGHTS AND RELATED TECHNOLOGY,
INCLUDING WITHOUT LIMITATION ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE. Specifically, Medical School makes no warranty or representation (a) regarding
the prosecution or the validity or scope of the Patent Rights, (b) that the exploitation of the
Patent Rights or any Licensed Product will not infringe any patents or other intellectual property
rights of a third party, and (c) that any third party is not currently infringing or will not
infringe the Patent Rights.

     10.2. Compliance with Law and Policies. Company agrees to comply with applicable law
and the policies of Medical School in the area of technology transfer and shall promptly notify
Medical School of any violation that Company knows or has reason to believe has occurred or is
likely to occur. The Medical School will provide current copies of the policies currently in effect
at the Worcester campus upon request.

     10.3. Tax-Exempt Status. Company acknowledges that Medical School, as a public
institution of the Commonwealth of Massachusetts, holds the status of an exempt organization under
the United States Internal Revenue Code. Company also acknowledges that certain facilities in which
the licensed inventions were developed may have been financed through offerings of tax-exempt
bonds. If the Internal Revenue Service determines, or if counsel to Medical School reasonably
determines, that any term of this

Page 16 of 20

 

 

UMass Agreement No. UMMC 03-33-06

Agreement jeopardizes the tax-exempt status of Medical School or the bonds used to finance Medical
School facilities, the relevant term shall be deemed an invalid provision and modified in
accordance with Section 10.11.

     10.4. Counterparts. This Agreement may be executed in one or more counterparts, each
of which shall be deemed an original, and all of which together shall be deemed to be one and the
same instrument.

     10.5. Headings. All headings are for convenience only and shall not affect the
meaning of any provision of this Agreement.

     10.6. Binding Effect. This Agreement shall be binding upon and inure to the
benefit of the parties and their respective permitted successors and assigns.

     10.7. Assignment. This Agreement may not be assigned by either party without the prior
written consent of the other party, except that Company may assign this Agreement to an Affiliate
or to a successor in connection with the merger, consolidation, or sale of all or substantially all
of its assets or that portion of its business to which this Agreement relates.

     10.8. Amendment and Waiver. This Agreement maybe amended, supplemented, or otherwise
modified only by means of a written instrument signed by both parties. Any waiver of any rights or
failure to act in a specific instance shall relate only to such instance and shall not be construed
as an agreement to waive any rights or fail to act in any other instance, whether or not similar.

     10.9. Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the Commonwealth of Massachusetts irrespective of any conflicts of law principles.
Both parties agree that any legal action arising out of or in connection with this Agreement shall
be brought in the Massachusetts Superior Court in Suffolk County.

     10.10. Notice. Any notices required or permitted under this Agreement shall be in
writing, shall specifically refer to this Agreement, and shall be sent by recognized national
overnight courier or registered or certified mail, postage prepaid, return receipt requested, to
the following addresses of the parties:

If to Medical School:

Office of Technology Management

 University of Massachusetts Medical School 

333 South Street, Suite 400 Shrewsbury, MA 

01545 Attention: Executive Director

If to Company:

Page 17 of 20

 

 

UMass Agreement No. UMMC 03-33-06

CytRx Corporation

11726 San Vicente Blvd., Suite 650

Los Angeles, CA 90049

Attention: Steven A. Kriegsman

                   Chief Executive Officer

All notices under this Agreement shall be deemed effective upon receipt. A party may
change its contact information immediately upon written notice to the other party in
the manner provided in this Section.

     10.11. Severability. In the event that any provision of this Agreement
shall be held invalid or unenforceable for any reason, such invalidity or
unenforceability shall not affect any other provision of this Agreement, and the
parties shall negotiate in good faith to modify the Agreement to preserve (to the
extent possible) their original intent. If the parties fail to reach a modified
agreement within sixty (60) days after the relevant provision is held invalid or
unenforceable, then the dispute shall be resolved in accordance with the procedures
set forth in Article 9. While the dispute is pending resolution, this Agreement
shall be construed as if such provision were deleted by agreement of the parties.

     10.12. Entire Agreement. This Agreement constitutes the entire
agreement between the parties with respect to its subject matter and supersedes all
prior agreements or understandings between the parties relating to its subject
matter.

     The parties have caused this Agreement to be executed by their duly authorized
representatives as of the Effective Date.

	 	 	 
	UNIVERSITY OF MASSACHUSETTS
MEDICAL SCHOOL	 	CYTRX CORPORATION

	 	 	 	 	 	 	 	 	 
	By:

	 	     /s/ Chester A. Bisbee
	 	 	 	By:
	 	/s/ Steven A Kriegsman
	 

	 	 
	 	 	 	 	 	 
	 

	 	Chester A. Bisbee
	 	 	 	 	 	Steven A. Kriegsman
	 

	 	Acting Director, OTM
	 	 	 	 	 	Chief Executive Officer

Page 18 of 20

 

 

EXHIBIT A List of Patent Rights UMMC 03-33

Invention Disclosure

Entitled “Chemically Modified siRNA and Uses Thereof

Provisional Application

“Chemically Modified siRNA and Uses Thereof

Tariq M. Rana, Ph.D. inventor

Filed 9/25/02 — Application No. 60/413,529

UMMC 03-61

Invention Disclosure

Entitled “In Vivo Gene Silencing by Chemically Modified and Stable siRNA”

Provisional Application

“In Vivo Gene Silencing by Chemically Modified and Stable siRNA”

Tariq M. Rana, Ph.D., inventor

Filed 11/15/02 — Application No. 60/426,982

UMMC 03-101

Invention Disclosure

Entitled “RNAi Modifications”

Provisional Application

“In Vivo Gene Silencing by Chemically Modified and Stable siRNA”
Tariq M. Rana, Ph.D., inventor
Filed 3/26/03 — Application No. 60/458,051

United States Application

“In Vivo Gene Silencing by Chemically Modified and Stable siRNA”

Tariq M. Rana, Ph.D., inventor

Filed 9/25/03 — Application No. 10/672,069

(Combined UMMC 03-33 UMMC 03-61 and UMMC 03-101 provisional applications)

 

 

Foreign Applications

International Patent Application No. PCT/US03/30480

“In Vivo Gene Silencing by Chemically Modified and Stable
siRNA“filed September 25, 2003. - (Combines UMMC 03-33, UMMC 03-61 and UMMC 03-101 provisional applications).

Australian Patent Application No. 2003282877 entitled “In Vivo Gene Silencing by Chemically Modified and Stable siRNA by Tariq M Rana, filed September 25, 2003.

European Patent Application No. 03774498.4 entitled “In Vivo Gene Silencing by Chemically Modified and Stable siRNA by Tariq M. Rana, filed September 25, 2003.

Canadian Patent Application No. 2500224 entitled “In Vivo Gene Silencing by Chemically Modified and Stable siRNA” by Tariq M. Rana, filed March 24, 2005.exv10w14

 

Exhibit 10.14

DATED May 19, 2004

 

IMPERIAL COLLEGE INNOVATIONS LIMITED

And

IMPERIAL COLLEGE OF SCIENCE AND TECHNOLOGY

And

CYTRX CORPORATION

 

PATENT LICENCE AGREEMENT

 

Birmingham London Brussels

Tel +44 (0)870 903 1000  Fax +44 (0)870 904 1099  mail@wragge.com  www.wragge.com

[***] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with the Commission.

 

 

THIS AGREEMENT is made on May 19, 2004

BETWEEN:

	(1)	 	IMPERIAL COLLEGE INNOVATIONS LIMITED (Registered in England No 2060639) whose registered
office is at Sherfield Building, Imperial College, London SW7 2AZ (“ICIL”), and
	 
	(2)	 	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE a college incorporated by royal charter,
of Exhibition Road, London SW7 2AZ (“Imperial”); and
	 
	(3)	 	CYTRX CORPORATION, a company established under the laws of the State of Delaware, U.S.A. and
having its principal place of business at 11726 San Vicente Boulevard, Suite 650, Los Angeles,
California 90049 USA (“CytRx”).

BACKGROUND:

	(a)	 	Professor Parker is a full-time employee of Imperial, engaged by Imperial to carry out
research. In the course of his normal employment duties for Imperial Professor Parker made
inventions and developed technology, materials and know-how relating to the potential role of
RIP140 in obesity and anorexia including without limitation inventions in respect of which a
patent application has been made (defined below as the “Patent Application”) and consequently
Professor Parker’s share in the Licensed Patents belongs to Imperial pursuant to Section 39 of
the Patents Act 1977. In order to further the clinical applications and commercial
exploitation of the above technology, Imperial has assigned to Innovations all its rights,
title and interest in the Patent Application and Materials under an assignment agreement dated
14th May 2004. Accordingly ICIL is the sole legal owner of the Patent Application and the
Materials.

 

 

	(b)	 	CytRx is a biopharmaceutical company dedicated to the commercialisation of high value human
therapeutics, including those for the treatment of obesity and diabetes.
	 
	(c)	 	CytRx wishes to obtain a licence to the Materials in the Field and the Licensed Patents (as
defined below).
	 
	(d)	 	ICIL is willing to grant a licence to CytRx under the conditions set out in this Agreement
including the payment of royalties and milestones.

In consideration of the mutual covenants and undertakings set out below, THE PARTIES AGREE as
follows:

	1	 	Definitions

	1.1	 	In this Agreement, the terms defined in this Clause shall have the meanings specified below:
	 
	 	 	“Affiliate” means any company, partnership or other entity which directly or indirectly
Controls, is Controlled by or is under common Control with any other entity.
	 
	 	 	“Agreement” means this agreement and any and all Schedules, appendices and other addenda to
it as may be amended from time to time in accordance with the provisions of this agreement.
	 
	 	 	“Biological Materials” means tangible biological or biochemical materials that are necessary
for the effective exercise of the Licensed Patents (e.g., reagents, cell lines, cDNAs, DNA
constructs, animal models), to the extent that Imperial is free and able to grant access
and commercialisation rights to such materials, which materials are set out in Schedule 2.
Schedule 2 shall be periodically amended by mutual consent to include any additional
Biological Materials that Imperial may furnish to CytRx.
	 
	 	 	“Business Day” means a day (other than a Saturday or Sunday) on which the banks are
ordinarily open for business in both the City of London and the City of Los Angeles.

 

 

	 	 	“Combination Product” means a product (for which Marketing Authorisation has been granted)
sold in the form of a combination product containing a Licensed Product as an active
component and one or more Other Elements. As used herein, “Other Elements” shall mean
either one or more active components which are not Licensed Products or one or more other
components (such as a delivery device) which are not Licensed Products.
	 
	 	 	“Commencement Date” means the date of this Agreement.
	 
	 	 	“Competent Authority” means any national or local agency, authority, department,
inspectorate, minister, ministry official, parliament or public or statutory person or other
entity (whether autonomous or not) of any government of any country having jurisdiction or
authority over either any of the activities and functions contemplated or described by this
Agreement or the Parties including the European Commission, the Court of First Instance and
the European Court of Justice.
	 
	 	 	“Confidential Information” means Know How and trade secrets or confidential information
relating to the business affairs or finances of the other Party supplied or otherwise made
available to them or coming into their possession in relation to the performance of this
Agreement, irrespective of form.
	 
	 	 	“Control” means either (a) in the case of (i) corporate entities, direct or indirect
ownership of at least fifty percent (50 %) of the stock or shares entitled to vote for the
election of director, (ii) non-corporate entities, direct or indirect ownership of at least
fifty percent (50 %) of the equity interest with the power to direct the management and
policies of such noncorporate entities or (b) with respect to any item of or right under the
Licensed Patents, the possession of (whether by ownership or licence, other than pursuant
to this Agreement) or the ability of a Party to grant access to, or a licence or sublicence
of, such item or right as provided for herein without violating the terms of any agreement
or other arrangement with any Third Party existing at the time such Party would be required
hereunder to grant the other Party such access or licence or sublicence. “Controls” and
“Controlled by” shall be construed accordingly.
	 
	 	 	“CytRx Foreground Improvements” has the meaning set out in Clause 7.1.

 

 

	 	 	“CytRx Materials Improvements” has the meaning set out in Clause 8.3.
	 
	 	 	“CytRx Sublicensee” means any Third Party that acquires rights to the use of the Materials
and under the Licensed Patents through CytRx or its Affiliates by virtue of this Agreement.
	 
	 	 	“Diagnostic Product” means any preparation in the form of a device, compound, kit or service
with utility in the diagnosis, prognosis, prediction or management of obesity, anorexia or
diabetes in humans which contains or comprises:

	 	(a)	 	either in its entirety or in shortened form the RIP140 gene or RIP140 gene
product howsoever modified including without limitation nucleotides, oligonucleotides,
nucleic acid vectors, peptides, polypeptides, proteins etc.; or
	 
	 	(b)	 	an agent that binds to the RIP140 gene or an RIP140 gene product (excluding the
RIP140 protein or any subunit thereof) with the purpose of enhancing, interfering with,
silencing, suppressing or modulating the expression thereof such agents including
without limitation complementary sequences, ligands, cDNA, mRNA, tRNA, antibodies,
antibody fragments, peptides, fusion proteins, mimetics, aptamers, antisense (or other
nucleic acid based gene or gene product modulators), ribozymes, molecular imprinted
polymers, RNAi, microRNA, dsRNA, siRNA, shRNA, vaccines, immunotherapeutics and gene
therapy products; or
	 
	 	(c)	 	an agent (including without limitation small molecule entities) that has a
mechanism of action through interaction with or binding to the RIP140 protein (or a
subunit thereof); and

	 	 	which have been identified by CytRx, a CytRx Affiliate or a CytRx Sublicensee as a direct
result of (i) the use of the Materials (or the use of an Improvement to the Materials
licensed to CytRx under Clauses 8.1 and/or 8.2) or (ii) an activity that falls within a
Valid Claim.

 

 

	 	 	“Directive” means any present or future directive, regulation, requirement, instruction,
direction or rule of any Competent Authority including any amendment, extension or
replacement thereof then in force.
	 
	 	 	“Disclosing Party” means a Party which discloses Confidential Information to another Party.
	 
	 	 	“Documents” means any graphic, written or computer readable material on which Know How can
be permanently stored.
	 
	 	 	“Exploit” means to develop, make, have made, use, have used, sell, have sold, or import, or
have imported and “Exploitation” shall be construed accordingly.
	 
	 	 	“FDA” means the United States Food and Drug Administration, the equivalent Competent
Authority in any country of the Territory or any successor bodies thereto.
	 
	 	 	“Field” means the in vitro or in vivo screening of compounds, molecules or compositions of
matter acting against or as agonists or antagonists of RIP140 to select compounds, molecules
or compositions of matter which may be useful in the treatment or prevention of obesity,
anorexia or diabetes.
	 
	 	 	“First Commercial Sale” means in respect of a Licensed Product the first commercial sale of
any such product by CytRx, a CytRx Affiliate or a CytRx Sublicensee in any country after
grant of a Marketing Authorisation.
	 
	 	 	“Force Majeure” means any event outside the reasonable control of either Party affecting its
ability to perform any of its obligations (other than payment) under this Agreement,
including Act of God, fire, flood, lightning, war, revolution, act of terrorism, riot or
civil commotion, but excluding strikes, lock-outs or other industrial action, whether of the
affected Party’s own employees or others, failure of supplies of power, fuel, transport,
equipment, raw materials or other goods or services.
	 
	 	 	“GAAP” means United States generally accepted accounting principles, consistently
applied.

 

 

	 	 	“Improvement” means any improvement or enhancement or modification, whether patentable or
otherwise.
	 
	 	 	“IND” means investigational new drug application filed with, and accepted by, the FDA prior
to Initiation of clinical trials in humans in the USA, or any comparable application filed
with the Regulatory Authority of a country or group of countries other than the U.S.A. or
any successor body thereto prior to Initiation of clinical trials in humans in that country
or in that group of countries.
	 
	 	 	“Initiation” of a clinical trial shall mean the enrolment of the first human subject into
the trial.
	 
	 	 	“Investigation Authorisation Application” means an IND, an IDE or any other equivalent
application not covered by an IND or IDE required by a Competent Authority anywhere in the
Territory.
	 
	 	 	“Know-How” means unpatented technical and other information which is not in the public
domain. Know-How includes Documents. The fact that an item is known to the public shall
not be taken to exclude the possibility that a compilation including the item, and/or a
development relating to the item, is (and remains) not known to the public. Know-How
includes any rights including copyright, database or design rights protecting such Know-How.
	 
	 	 	“Licensed Patents” means (a) the Patent Application listed in Schedule 1 which may be
updated from time to time as applicable and as mutually agreed between the Parties, and any
non-provisional applications claiming priority thereto; (b) any patents issued from any such
applications described in (a) anywhere in the world; (c) any divisions, registrations,
confirmations, reissues, re-examinations, extensions, renewals, continuations,
continuations-in-part, revalidations, additions, substitutions, or renewals entitled to
claim priority to any such patent applications or patents described in (a); and (d) all
national, regional and foreign counterparts or other forms of protection, including
supplementary protection certificates, claiming priority from the patents or patent
applications described in (a) to (c) above.

 

 

	 	 	“Licensed Product” means any preparation for the treatment or prevention of obesity,
anorexia or diabetes in humans that:

	 	(d)	 	incorporates either in its entirety or in shortened form the RIP140 gene or
RIP140 gene product howsoever modified including without limitation nucleotides,
oligonucleotides, nucleic acid vectors, peptides, polypeptides, proteins etc.; or
	 
	 	(e)	 	is an agent that binds to the RIP140 gene or an RIP140 gene product (excluding
the RIP140 protein or any subunit thereof) with the purpose of enhancing, interfering
with, silencing, suppressing or modulating the expression thereof such agents including
without limitation complementary sequences, ligands, cDNA, mRNA, tRNA, antibodies,
antibody fragments, peptides, fusion proteins, mimetics, aptamers, antisense (or other
nucleic acid based gene or gene product modulators), ribozymes, molecular imprinted
polymers, RNAi, microRNA, dsRNA, siRNA, shRNA, vaccines, immunotherapeutics and gene
therapy products; or
	 
	 	(f)	 	is an agent (including without limitation small molecule entities) that has a
mechanism of action through interaction with or binding to the RIP140 protein (or a
subunit thereof); and

	 	 	which have been identified by CytRx, a CytRx Affiliate or a CytRx Sublicensee as a direct
result of (i) the use of the Materials (or the use of an Improvement to the Materials
licensed to CytRx under Clauses 8.1 and/or 8.2) or (ii) an activity that falls within a
Valid Claim.
	 
	 	 	“Licence” has the meaning set out in Clause 2.1.
	 
	 	 	“Licensed Services” means services using the Licensed Patents, Materials or Licensed
Products (for example a screening service against RIP140, where such service is provided to
a Third Party).
	 
	 	 	“Major Market” means any one of the following: (i) the United States of America, (ii) the
European Union, (iii) Japan, (iv) Canada or (v) Australia.

 

 

	 	 	“Marketing Authorisation” means any approval (including all applicable pricing and
governmental reimbursement approvals in those countries where such approvals are necessary
to sell medicines to a substantial segment of that country’s market for the medicine that is
the subject of the marketing authorisation) required from the FDA or relevant Competent
Authority to market and sell a Licensed Product in a particular country.
	 
	 	 	“Marketing Authorisation Application” means an application for a Marketing Authorisation
including but not limited to a New Drug Application or a Biologics License Application as
required by the FDA or its foreign equivalents.
	 
	 	 	“Materials” means Biological Materials and Related Technology.
	 
	 	 	“Net Sales Value” means in relation to any Licensed Product, the gross invoice price of
Licensed Products sold, leased or disposed of by or on behalf of CytRx (including by any
CytRx Affiliate or CytRx Sublicensee) to independent third parties in arm’s length
transactions exclusively for money or where a transaction is not at arm’s length the price
which would have been invoiced if the transaction had been at arms length less the following
deductions applicable to the Licensed Product for:

	 	(a)	 	transportation charges and insurance charges paid by or on behalf of CytRx (or
any CytRx Affiliate or CytRx Sublicensee);
	 
	 	(b)	 	sales and excise taxes or customs duties paid by or on behalf of CytRx (or any
CytRx Affiliate or CytRx Sublicensee) or any other governmental charges imposed upon
the sale of the Licensed Product and paid by or on behalf of CytRx (or any CytRx
Affiliate or CytRx Sublicensee) (excluding income, corporation or similar taxes);
	 
	 	(c)	 	fees paid to distributors, consignees or agents in connection with the sale of
the Licensed Product;
	 
	 	(d)	 	rebates and premiums actually granted or allowed in connection with the sale of
a Licensed Product;

 

 

	 	(e)	 	allowances or credits actually given to customers on account of governmental
requirements, price differences, rejection, outdating, returns or recalls of the
Licensed Product;
	 
	 	(f)	 	quantity discounts, cash discounts or chargebacks actually granted in
connection with the sale of the Licensed Product; and
	 
	 	(g)	 	provisions for price reductions actually given after any sale of a product, for
example but not by way of limitation for late delivery.

If an invoice in respect of the sale or lease of Licensed Products has not been paid within
four months of the due date for payment of the invoice then ICIL shall credit (against
future royalties, milestones and other amounts payable to ICIL) CytRx in respect of any
royalties paid on such invoice (a “Bad Debt Credit”). The Bad Debt Credit will be given in
respect of the Quarter in which the date four months from the due date for payment of the
invoice falls. Should CytRx subsequently be paid in relation to an invoice in respect of
which a Bad Debt Credit has been given then royalties on such invoice will again become
payable by CytRx. The royalties will be payable in respect of the Quarter in which the
payment is received.

No royalties shall be payable by CytRx to ICIL in relation to any disposals of Licensed
Products among CytRx and any of CytRx’s Affiliates (or any CytRx Sublicensee or any
Affiliates of such CytRx Sublicensee) provided that the recipient does not consume or use
the Licensed Products save for testing, quality control and research and development
purposes where such testing, quality control and research and development relates to the
testing, quality control and research and development of such Licensed Products. No
royalties shall be paid on any sales or donations of Licensed Products by CytRx (or any
CytRx Affiliate or CytRx Sublicensee) at or below CytRx’s (or CytRx Affiliate’s or CytRx
Sublicensee’s) fully loaded cost for the Licensed Products as part of any government or
other charitable assistance program.

In the event that a Licensed Product is sold as part of a Combination Product in any
country, the Net Sales Value of the Licensed Product in that country for the purposes of

 

 

determining royalty payments shall be determined by multiplying the Net Sales Value of the
Combination Product in that country by the fraction (A/A+B) where A is the average sale
price in the relevant Quarter (as hereinafter defined) of the Licensed Product in that
country when sold separately in finished form and B is the average sale price in the
relevant Quarter of the Other Element in that country sold separately in finished form.

In the event that the average sale price of the Licensed Product in that country can be
determined but the average sale price of the Other Element in that country cannot be
determined, the Net Sales Value of the Licensed Product in that country for the purposes of
determining royalty payments shall be calculated by multiplying the Net Sales Value of the
Combination Product in that country by the fraction (C/D) where C is the selling Party’s
average sales price in the relevant Quarter of the Licensed Product and D is the average
selling price in the relevant Quarter of the Combination Product in that country.

If the average sale price of the Other Element in that Quarter can be determined but the
average price of the Licensed Product in that country cannot be determined, Net Sales Value
of the Combination Product in that country for the purposes of determining royalty payments
shall be calculated by multiplying the Net Sales Value of the Combination Product in that
country by the following formula: one (1) minus E/D where E is the average selling price in
the relevant Quarter of the Other Element in that country and D is the average selling price
of the Combination Product in that country in the relevant Quarter.

If the average sale price of both the Product and the Other Element cannot be determined,
the Net Sales Value of Product shall be reasonably agreed upon by the Parties and if the
Parties fail to agree on a calculation method within thirty (30) days of commencing
negotiations the matter shall be referred to Expert’s Decision Procedure in Schedule 3.

“Non-Commercially Sensitive” means that CytRx in its sole discretion has determined that (a)
no information relating to the CytRx Foreground Improvement is confidential and (b) it does
not wish to Exploit such an Improvement itself or by way of the grant of commercial
licences.

 

 

“Non-Severable Improvement” means an Improvement to the technology disclosed in the Licensed
Patents that cannot be Exploited without infringing a Valid Claim of the Licensed Patents.

“Option Notice” has the meaning set out in Clause 15.1.

“Party” means ICIL, Imperial or CytRx.

“Patent Application” means the PCT application PCT/2004/000413 filed on 3rd
February 2004 and claiming priority from UK priority patent application number 0302446.0
filed 3rd February 2003 entitled “Screening for Modulators of Fat Storage”.

“Patenting Territories” means USA, Canada, Australia, Europe (EPO designating all states),
Japan, New Zealand and Mexico.

“Patent Rights” – shall mean patent applications and patents, author certificates, inventor
certificates, utility certificates, improvement patents and models and certificates of
addition and all foreign counterparts thereof, including any divisional applications and
patents, refilings, renewals, continuations, continuations-in-part, patents of addition,
extensions, reissues, substitutions, confirmations, registrations, revalidation and
additions of or to any of them, as well as any supplementary protection certificates and
equivalent protection rights in respect of any of them.

“Phase I Clinical Trial” means the first administration of a Licensed Product in human
subjects that would satisfy the requirements of 21 CFR 312.21(a) or its non-U.S.A.
equivalent.

“Phase II Clinical Trial” means a human clinical trial in any country that is intended to
initially evaluate the effectiveness of a Licensed Product in the targeted patient
population for a particular indication or indications in human subjects with the disease or
indication under study that would satisfy the requirements of 21 CFR 312.21(b) or its
non-U.S.A. equivalent.

 

 

“Phase III Clinical Trial” means a controlled human clinical trial in any country involving
patients with the disease or condition of interest the results of which could be used to
establish safety and efficacy of a Licensed Product as a basis for a Marketing Authorisation
that would satisfy the requirements of U.S. 21 CFR 312.21(c) or its non-U.S.A. equivalent.

“Quarter” means each period of three (3) months ending on March 31, June 30, September
30, or December 31 and “Quarterly” shall be construed accordingly.

“Recipient Party” means a Party that receives Confidential Information from another Party.

“Related Technology” means Know-How, technical information, research and development
information, test results, and data necessary for the effective exercise of the Licensed
Patents by the Licensee in order to identify and/or generate and/or develop Licensed
Products and/or Diagnostic Products which are Controlled by ICIL and have been developed by
the Research Group .

“Research Group” means Professor Malcolm Parker and/or his associates in their laboratories
at the Institute of Reproductive and Developmental Biology at Imperial.

“RIP140” means (a) nuclear receptor interacting protein 140 also known as Nrip1 (nuclear
receptor interacting protein 1), and /or (b) a target protein for nuclear receptor
interacting protein 140 and/or (c) a complex of nuclear receptor interacting protein 140 and
its target protein(s).

“Royalty” means the sums payable by CytRx to ICIL based on Net Sales Value of Licensed
Products as set out in Clauses 4.11 to 4.13.

“Severable Improvement” means an Improvement to the technology disclosed in the Licensed
Patents that can be Exploited without infringing a Valid Claim of the Licensed Patents.

“Signature Fee” has the meaning set out in Clause 4.1.2.

 

 

“Sublicensing Revenue” means milestone payments and upfront fees that CytRx receives from a
CytRx Sublicensee in consideration of a sublicence of the Licence (in whatever form, for
example but not limited to cash, warrants, loans, debentures, swaps etc.), but excluding the
following payments: (a) royalties, (b) payments made in consideration for the issuance of
equity or debt securities of CytRx at fair market value (taking into account customary
discounts for restricted securities), and (c) payments specifically committed to the
development of Licensed Products, Diagnostic Products or Licensed Services on behalf, or for
the benefit of a Sublicensee subject to such payments and their application to such
development being available for audit under clause 5.7 .

“Third Party” means any person or entity other than ICIL, Imperial or CytRx and their
respective Affiliates.

“U.S.A.” means the United States of America and its territories, possessions and
commonwealths.

“Valid Claim” means a claim of an issued and unexpired patent included within the Licensed
Patents which has not been held permanently revoked, unenforceable or invalid by a decision
of a court or other governmental agency of competent jurisdiction unappealed within the time
allowed for appeal, and which has not been admitted to be invalid or unenforceable through
reissue or disclaimer or otherwise.

“Year” means the period of twelve months commencing on the Commencement Date and on each
successive anniversary of the Commencement Date and ending on the day before each successive
anniversary of the Commencement Date.

	1.2	 	The headings to clauses are inserted for convenience only and shall not affect the
interpretation or construction of this Agreement.
	 
	1.3	 	Words imparting the singular shall include the plural and vice versa. References to persons
include an individual, company, corporation, firm or partnership.

 

 

	1.4	 	The words and phrases “other”, “including” and “in particular” shall not limit the generality
of any preceding words or be construed as being limited to the same class as any preceding
words where a wider construction is possible.
	 
	1.5	 	References to any statute or statutory provisions of the United Kingdom, the USA or the
European Union, shall include (i) any subordinate legislation made under it, (ii) any
provision which it has superseded or re-enacted (whether with or without modification), and
(iii) any provision which subsequently supersedes it or re-enacts it (whether with or without
modification).
	 
	2	 	Grant of Licence 
	 
	2.1	 	ICIL grants to CytRx and, and for such time as they hold that status, its Affiliates:

	 	2.1.1	 	a worldwide, exclusive licence, with the right to grant sublicences, under the
Licensed Patents to do all acts which would otherwise infringe the Licensed Patents
including, without limitation, the right to Exploit the Licensed Products and
Diagnostic Products and provide Licensed Services or otherwise do all acts which would
otherwise infringe a Valid Claim of the Licensed Patents; and
	 
	 	2.1.2	 	a worldwide, exclusive license, with the right to grant sublicenses in
connection with a grant of sublicences of the Licensed Patents, to use the Biological
Materials in the Field, including, without limitation, the right to Exploit the
Licensed Products and Diagnostic Products and provide Licensed Services; and
	 
	 	2.1.3	 	a worldwide, non-exclusive license, with the right to grant sublicenses in
connection with a grant of sublicences of the Licensed Patents, to use the Related
Technology in the Field, including, without limitation, the right to Exploit the
Licensed Products and Diagnostic Products and provide Licensed Services

(all the licences in this Clause 2.1 being the “Licence”).

	2.2	 	CytRx and/or its Affiliates grants to ICIL and Imperial an irrevocable, royalty-free,
non-assignable (other than to successors in business), non-sublicensable, non-exclusive

 

 

	 	 	license for (a) ICIL and Imperial and every employee, student, agent and appointee of
Imperial to use the Licensed Patents, Materials and Related Technology solely for internal
non-commercial academic research and teaching purposes and (b) for ICIL and Imperial to make
the Licensed Patents, Materials and Related Technology available to other academic
institutions solely for non-commercial research and teaching purposes under written material
transfer agreements that adequately protect any intellectual property rights created through
such research; provided that in the case of both (a) and (b) and subject to Clause
2.3, ICIL and/or Imperial shall not jeopardize the confidential nature of any Know-How.
Imperial shall have the right to use the Licensed Patents, Materials and Related Technology
as enabling technology in non-commercial research projects, including projects which benefit
from external funding.

	2.3	 	If Imperial’s scientific research activities conducted by the Research Group for
non-commercial purposes in relation to the Materials in the Field or Licensed Patents or
Improvements licensed to Imperial under Clause 7.2 where such Improvements have been disclosed
to the Research Group at Imperial produce information that Imperial wishes to present or
publish within twenty four (24) months of the date of this Agreement, then the proposed text
shall be disclosed to CytRx in advance of its submission for presentation or publication.
CytRx shall have thirty (30) Business Days to review the text during which period the
information may not be presented or published. CytRx may suggest amendments or omissions to be
made to any proposed text, which Imperial shall reasonably accept, provided that such
amendments are reasonably necessary to prevent any commercial damage to CytRx except where
failure to publish would materially prevent the advancement of medical science;

	2.4	 	If Imperial’s scientific research activities conducted by the Research Group for
non-commercial purposes in relation to the:

	 	2.4.1	 	Materials within the Field,
	 
	 	2.4.2	 	Licensed Patents within the Field; or

 

 

	 	2.4.3	 	Improvements within the Field licensed to Imperial under Clause 7.2 where such
Improvements have been disclosed to the Research Group at Imperial

produce information that Imperial wishes to present or publish after twenty four (24) months
of the date of this Agreement, then Imperial shall use reasonable efforts to ensure that the
proposed text shall be disclosed to CytRx at least thirty (30) days in advance of its
submission for presentation or publication.

	2.5	 	Sub-licensing.
	 
	 	 	CytRx shall be entitled to grant sub-licences of its rights under the terms and conditions
of Clause 2.1 of this Agreement to any person, provided that:

	 	(a)	 	the sub-licence shall include performance and financial obligations on the
sub-licensee which are at least equivalent to the obligations on CytRx under this
Agreement;
	 
	 	(b)	 	the sub-licence shall continue following the termination of this Agreement for
any reason as a licence between ICIL and the sub-licensee pursuant to clause 14.5.2,
provided that if the royalties and other consideration provided for in the sub-licence
are less that that provided for in this Agreement such royalties or other consideration
shall be increased to be the same as provided for in this Agreement and further
provided that the sub-licensee agrees in writing to such new financial terms and to the
substitution of CytRx by ICIL;
	 
	 	(c)	 	within thirty (30) days of the grant of any sub-licence CytRx shall provide to
ICIL a summary of the material terms of the sub-licence and a written agreement from
the sub-licensee to be bound by the provisions of this Agreement to the extent
applicable;
	 
	 	(d)	 	except in the case of the continuation of the licence pursuant to Clause 2.5(b)
CytRx shall be responsible for any breach of the sub-licence by the sub-licensee, as if
the breach had been that of CytRx under this

 

 

	 	 	 	Agreement, and CytRx shall indemnify ICIL against any loss, damages, costs,
claims or expenses which are awarded against or suffered by ICIL as a result
of any such breach by the sub-licensee; and
	 
	 	(e)	 	no sub-licence shall carry any right to sub-sub-licence all of the rights
granted to CytRx under this Agreement without the consent of ICIL (such consent not to
be unreasonably withheld) save that a sub-licence can be sub-licensed for the purposes
of manufacture or co-marketing without the consent of ICIL.

	2.6	 	CytRx shall use commercially reasonable endeavours to ensure that all of the Licensed
Products marketed by it and its sub-licensees are of satisfactory quality and comply with all
material applicable laws in each country. CytRx shall maintain, or cause a CytRx Sublicensee
to maintain, adequate product liability insurance from the date of first commercial sale of a
Licensed Product for the term of this Agreement.
	 
	2.7	 	CytRx or any CytRx Sublicensees shall be exclusively responsible for the technical and
commercial development and manufacture of Licensed Products and for incorporating any
modifications or developments thereto that may be necessary or desirable and for all Licensed
Products sold or supplied, and accordingly CytRx shall indemnify ICIL in the terms of Clause
12.7.

	3	 	Materials
	 
	3.1	 	Within a reasonable time after the Commencement Date Imperial will, at the cost of CytRx, and
in accordance with shipping instructions from CytRx, deliver sufficient Materials as set out
in Schedule 2 to CytRx at its laboratories in Worcester, Massachusetts, U.S.A. to allow CytRx
to develop RIP140 screening assays and functional assays in their own laboratories.
	 
	4	 	Consideration
	 
	4.1	 	In consideration of the grant of the Licence to CytRx, CytRx shall on signature of this
Agreement:

 

 

4.1.1 allot and issue to ICIL, credited as fully paid, {***} shares of common stock in CytRx
(the “Consideration Shares”); and

4.1.2 pay ICIL {***} (the “Signature Fee”).

	4.2	 	In the event of a delisting from Nasdaq of the Consideration Shares within the Lock In Period
(as defined below):

	 	4.2.1	 	the Consideration Shares shall be immediately cancelled and returned to CytRx;
and
	 
	 	4.2.2	 	CytRx shall pay ICIL {***}.

	4.3	 	The Consideration Shares will rank pari passu in all respects with the existing issued shares
of CytRx common stock. CytRx shall cause the consideration shares to be listed on the Nasdaq
Small Cap market or such other principal market on which CytRx’s common stock is then traded.
	 
	4.4	 	Subject to Clause 4.5, the Consideration Shares shall not be sold, disposed of or otherwise
transferred (in whole or part) by ICIL for a period of seven (7) months after the
Commencement Date (the “Lock In Period”). Any public resale of the Consideration Shares after
the Lock In Period will be subject to compliance with all U.S. securities laws, which require
the registration of those shares or an applicable exemption from registration, such as the
rule known as “Rule 144”. CytRx agrees that upon signature of this Agreement, CytRx will use
its commercially reasonable best efforts to comply with all U.S. securities laws in order for
ICIL to be in a position to execute a public resale of the Consideration Shares immediately
after the Lock In Period and will file a registration statement with the US Securities and
Exchange Commission covering ICIL’s public resale of the Consideration Shares and use its
commercially reasonable best efforts to have that registration become effective prior to the
end of the Lock In Period. ICIL will provide reasonable assistance to CytRx in this regard .
	 
	4.5	 	The Consideration Shares will be transferable by ICIL to the inventors of the Licensed
Patents before the end of the Lock In Period but the inventors will be not be able to

 

 

	 	 	further sell, dispose of or transfer such Consideration Shares (in whole or part) during the
Lock in Period.
	 
	 	 	Milestones
	 
	4.6	 	Subject to Clauses 4.7, 5.4 and 5.5, CytRx shall pay to ICIL the following payments upon
achievement of the specified milestones by CytRx or a CytRx Affiliate or a CytRx Sublicensee
for the first Licenced Product to reach such milestone:

	 	 	 
	Payable upon Initiation of the first Phase I Clinical Trial
	 	{***}
	 
	 	 
	Payable upon Initiation of the first Phase II Clinical Trial
	 	{***}
	 
	 	 
	Payable upon Initiation of the first Phase III Clinical Trial
	 	{***}
	 
	 	 
	Payable upon first grant of Marketing Authorisation in a Major Market
	 	{***}

	4.7	 	CytRx shall pay to ICIL {***} of any Sublicensing Revenue. In relation to milestone payments,
if {***} of any milestone payment received by CytRx from a CytRx Sublicensee is less than the
sum payable by CytRx in respect of the same milestone under Clause 4.6, then CytRx shall pay
ICIL the amount set out in Clause 4.6.
	 
	4.8	 	If CytRx is paid any Sublicensing Revenue in the form of non-cash consideration, ICIL and
CytRx will meet to agree the value of such non-cash consideration and the {***} proportion
payable to ICIL will be paid immediately (unless otherwise agreed between the parties) by
CytRx to ICIL, at the option of CytRx, in cash or in kind. If CytRx and ICIL cannot agree,
then the issue will be referred to the Expert’s Decision Procedure in Schedule 3.
	 
	4.9	 	CytRx shall pay to ICIL {***} of any fees received by CytRx from the provision by CytRx of
Licensed Services.
	 
	4.10	 	CytRx shall notify ICIL in writing within thirty (30) days upon the achievement of each
milestone set forth in Clause 4.6 and shall make the appropriate milestone payment within
thirty (30) days of the achievement of such milestone.

 

 

	 	 	Royalties
	 
	4.11	 	Subject to Clause 4.12, CytRx shall pay to ICIL a royalty of {***} of Net Sales Value of
Licensed Product(s) sold by CytRx or a CytRx Affiliate or a CytRx Sublicensee. CytRx shall
only be obliged to pay royalties to ICIL on sales by a CytRx Sublicensee or a CytRx Affiliate
on receipt by CytRx of royalty payments from a CytRx Sublicensee or a CytRx Affiliate in
respect of such sales.
	 
	4.12	 	Where in addition to the rights licensed by ICIL to CytRx under this Agreement, CytRx (or a
CytRx Affiliate or CytRx Sublicensee) requires one or more licences from a Third Party to
carry out research in relation to, or Exploit, a Licensed Product (each, a “Third Party
Licence”) because, absent such Third Party Licence, CytRx’s (or a CytRx Affiliate or CytRx
Sublicensee’s) research relating to, or the Exploitation of, the Licensed Product would
infringe a claim of a patent or patent application or other intellectual property of such
Third Party, the provisions of this Clause 4.12 shall apply. Any royalty payments on Licensed
Products due to such Third Party from CytRx (or a CytRx Affiliate or CytRx Sublicensee) under
any Third Party Licence shall be credited against any royalty payments due to ICIL under
Clause 4.11, provided however, that under no circumstances shall the aggregate of the set offs
in this Clause 4.12 reduce the royalty rate for payments due to ICIL from CytRx under Clause
4.11 to below {***}.
	 
	4.13	 	CytRx shall pay to ICIL a royalty of {***} of Net Sales Value (such definition being varied
mutatis mutandis to substitute Diagnostic Products for Licensed Products) of Diagnostic
Product(s) sold by CytRx or a CytRx Affiliate or a CytRx Sublicensee. CytRx shall only be
obliged to pay royalties to ICIL on sales by a CytRx Sublicensee on receipt by CytRx of
royalty payments from a CytRx Sublicensee in respect of such sales.
	 
	4.14	 	All royalties due to ICIL under this Agreement for any Licensed Product shall be payable on a
country-by-country basis until the last Valid Claim for that country expires.
	 
	4.15	 	For the purpose of calculating royalties under this Clause 4, a Licensed Product or a
Diagnostic Product shall be regarded as sold, leased or licensed by CytRx when invoiced, or if
not invoiced, when shipped or delivered by CytRx. If a Licensed Product is

 

 

	 	 	transferred to and further sold on by an Affiliate, the royalty on each
such Licensed Product shall be calculated on prices at which it is sold
by the Affiliate; provided, however, that in no event shall royalty be
paid more than once on each Licensed Product.

	5	 	Provisions relating to Payment of Consideration
	 
	5.1	 	All sums payable under this Agreement by CytRx shall be paid in US Dollars. For any payment
to CytRx (where ICIL is due a share of that payment) and where CytRx receives the payment in a
currency other than US Dollars, CytRx will convert the relevant sum due to ICIL into US
Dollars. CytRx will use the conversion rate reported in the Wall Street Journal two (2)
Business Days before the day on which CytRx pays ICIL.
	 
	5.2	 	Within fifty (50) days of the end of each Quarter (and within fifty (50) days of termination
of this Agreement) after the First Commercial Sale of each Licensed Product in any country,
CytRx shall prepare a statement which shall show on a country-by-country basis for the
previous Quarter all monies due to ICIL under Clause 4.11. That statement shall include
details of Net Sales Value showing the country of the sales and the total Net Sales Value on a
Licensed Product by Licensed Product and/or Diagnostic Product by Diagnostic Product basis
together with the quantities sold in such country and shall be submitted to ICIL within such
fifty (50) day period together with remittance of the monies due.
	 
	5.3	 	All lump sum payments under this Agreement (including the Signature Fee and milestone
payments) shall be paid by CytRx within thirty (30) days of the due date (which in the case of
milestone payments shall be in accordance with Clause 4.10).
	 
	5.4	 	If the US$/£ rate exceeds 2.00:1.00 at the time that a milestone payment is due under Clause
4.10 then that milestone payment will be increased using the following formula:

	 	5.4.1	 	If the US$/£ rate (as shown in the Wall Street Journal averaged over the five
Business Days before that milestone payment is due under Clause 4.10) is between 2.0001
and 2.1000 then the appropriate milestone payment set out in Clause 4.6 will be
increased by seven and a half percent (7.5%);

 

 

	 	5.4.2	 	If the US$/£ rate (as shown in the Wall Street Journal averaged over the five
Business Days before that milestone payment is due under Clause 4.10) is between 2.1001
and 2.2000 then the appropriate milestone payment set out in Clause 4.6 will be
increased by twelve percent (12.0%);
	 
	 	5.4.3	 	If the US$/£ rate (as shown in the Wall Street Journal averaged over the five
Business Days before that milestone payment is due under Clause 4.10) is between 2.2001
and 2.3000 then the appropriate milestone payment set out in Clause 4.6 will be
increased by sixteen percent (16.0%); and
	 
	 	5.4.4	 	If the US$/£ rate (as shown in the Wall Street Journal averaged over the five
Business Days before that milestone payment is due under Clause 4.10) increases above
2.3000 then the appropriate milestone payment set out in Clause 4.6 will be not be
increased by more than sixteen percent (16.0%).

	5.5	 	If the US$/£ rate goes below 1.700:1.000 at the time that a milestone payment is due under
Clause 4.10 then that milestone payment will be decreased using the following formula:

	 	5.5.1	 	If the US$/£ rate (as shown in the Wall Street Journal averaged over the five
Business Days before that milestone payment is due under Clause 4.10) is between
1.69999 and 1.69000 then the appropriate milestone payment set out in Clause 4.6 will
be decreased by seven and a half percent (7.5%);
	 
	 	5.5.2	 	If the US$/£ rate (as shown in the Wall Street Journal averaged over the five
Business Days before that milestone payment is due under Clause 4.10) is between
1.68999 and 1.68000 then the appropriate milestone payment set out in Clause 4.6 will
be decreased by twelve percent (12.0%);
	 
	 	5.5.3	 	If the US$/£ rate (as shown in the Wall Street Journal averaged over the five
Business Days before that milestone payment is due under Clause 4.10) is between
1.67999 and 1.67000 then the appropriate milestone payment set out in Clause 4.6 will
be decreased by sixteen percent (16.0%); and

 

 

	 	5.5.4	 	If the US$/£ rate (as shown in the Wall Street Journal averaged over the five
Business Days before that milestone payment is due under Clause 4.10) falls below
1.67:1 then the appropriate milestone payment set out in Clause 4.6 will not be
decreased by any more than sixteen percent (16.0%).

	5.6	 	All payments shall be made free and clear of and without deduction or deferment in respect of
any disputes or claims whatsoever and/or as far as is legally possible in respect of any taxes
imposed by or under the authority of any government or public authority. Any tax (other than
VAT) which CytRx is required to pay or withhold in respect of the payments to be made to ICIL
hereunder shall be deducted from the amount otherwise due provided that, in regard to any such
deduction, CytRx shall give ICIL reasonable assistance, which shall include the provision of
such documentation as may be required by any revenue authority and other revenue services, as
may be necessary to enable ICIL to claim exemption therefrom or obtain a repayment thereof or
a reduction thereof and shall upon request provide such additional documentation from time to
time as is needed to confirm the payment of tax.
	 
	5.7	 	CytRx shall keep and shall procure that CytRx Sublicensees keep true and accurate records and
books of account containing all data necessary for the production of the royalty statements
under Clause 5.2 and the calculation of the amounts payable by it to ICIL pursuant to this
Agreement. Those records and books of account shall be kept for two (2) years following the
end of the Year to which they relate. Upon ICIL’s written request and, except as set forth in
Clause 5.7.6, at ICIL’s expense, a firm of independent certified accountants appointed by ICIL
(which accountants shall not have performed auditing or other services for any Party or their
Affiliates):

	 	5.7.1	 	shall be given access to and shall be permitted to examine and copy any books
and records of CytRx, its Affiliates Sublicensees at all reasonable times on Business
Days in a manner calculated so as not to disturb the business affairs of the auditee
for the purpose of certifying that the Net Sales Value or other relevant sums
calculated by CytRx, its Affiliates and Sublicensees during any Year and previous
Years were reasonably calculated, true and accurate or, if this is not their

 

 

	 	 	 	opinion, certify the Net Sales Value figure or other relevant sums for such period
which in their judgment is true and correct;
	 
	 	5.7.2	 	the examination in Clause 5.7.1 may cover books and records that are in
existence and currently held by Cytrx, its Affiliates or Sublicensees at the date of
the inspection;
	 
	 	5.7.3	 	prior to any such examination taking place, such firm of accountants shall
undertake to CytRx that they shall keep all information and data contained in such
books and records, strictly confidential and shall not disclose such information or
copies of such books and records to any third person including ICIL, but shall only use
the same for the purpose of calculations which they need to perform in order to issue
the certificate to which this Clause envisages;
	 
	 	5.7.4	 	any such access examination and certification shall occur no more than once
per Year, save that in the event that the certification of the accountant shows that
CytRx has underpaid sums to ICIL by more than the greater of five thousand US Dollars
($5,000) and five percent (5%) of the amount properly owing, such access, examination
and certification shall occur no more than twice in the Year following the
certification of such discrepancy;
	 
	 	5.7.5	 	CytRx and CytRx Sublicensees shall make available personnel to answer queries
on all books and records required for the purpose of that certification; and
	 
	 	5.7.6	 	the cost of the accountant shall be the responsibility of CytRx if the
certification shows it to have underpaid monies to ICIL by more than the greater of
five thousand US Dollars ($5,000) and five percent (5%) of the amount properly owing,
or shall be the responsibility of ICIL otherwise.

	5.8	 	If the accountant concludes that additional royalties or other sums under this Agreement were
owed for the two (2) year period prior to the inspection, CytRx shall pay the additional
royalties or other sums within thirty (30) days of the date ICIL delivers to CytRx such
accountant’s written report so concluding. No additional royalties or other sums under this
Agreement shall be payable by CytRx in relation to any period more than

 

 

	 	 	two (2) years before any inspection. In the event that the accountant concludes that there
has been an overpayment of royalties or other sums under this Agreement, then subject to
Clause 14.5.5, the amount of the overpayment shall be credited against the next and any
following royalty or milestone payments of CytRx under this Agreement.

	5.9	 	No royalties payable by CytRx to ICIL shall be refundable or creditable against any other sum
payable by CytRx to ICIL under this Agreement.
	 
	5.10	 	All payments due to ICIL under the terms of this Agreement are expressed to be exclusive of
value added or other sales tax howsoever arising.
	 
	5.11	 	All payments made to ICIL under this Agreement shall be made to the bank account of ICIL as
notified by ICIL to CytRx from time to time.

	6	 	Conduct in relation to the Field
	 
	6.1	 	CytRx shall, at its own expense, use Reasonable Commercial Efforts to develop and
commercialise at least one Licensed Product (being either a product directed at the treatment
or prevention of obesity or a product directed at the treatment or prevention of diabetes or a
product directed at the treatment or prevention of both clinical indications) under the
Licence. For the purposes of this Clause 6.1 “Reasonable Commercial Efforts” shall mean
efforts which are similar to the efforts used by CytRx in pursuing the development,
commercialisation and marketing of other products under similar commercial circumstances that
have similar commercial value, status and potential to the Licensed Product in question. In
the event that CytRx has not developed any other products under similar commercial
circumstances that have similar commercial value, status and potential to the Licensed Product
in question then the efforts of CytRx shall be those employed by similar companies to CytRx in
terms of their size and financial resources. Notwithstanding the foregoing, and for the
avoidance of doubt, CytRx shall not be required by this Clause 6.1 or otherwise to continue
with its commercialisation or development efforts of any Licensed Product in any country if
for safety, efficacy, technical or reasonable business reasons it decides in good faith to
abandon the same.

 

 

	6.2	 	CytRx shall provide a report to ICIL on each anniversary of the Commencement Date which shall
be deemed Confidential Information and shall include:

	 	6.2.1	 	the status and any outcomes of research and development carried out by CytRx,
any CytRx Affiliate or CytRx Sublicensee in the Field;
	 
	 	6.2.2	 	a general statement on the progress of the development by CytRx,any CytRx
Affiliate or CytRx Sublicensee of Licensed Products;
	 
	 	6.2.3	 	in addition to CytRx’s ongoing obligation under Clause 4.10, confirmation of
the achievement of any of the milestones in Clause 4.6 by CytRx, its Affiliates or
Sublicensees; and
	 
	 	6.2.4	 	following the payment of the milestone payment payable upon Initiation of the
first Phase II Clinical Trial a commercialisation plan showing all past, current and
proposed actions by CytRx, a CytRx Affiliate of CytRx Sublicensee to market any
Licensed Product that has reached at least the Initiation of a Phase II Clinical Trial.

	6.3	 	Any failure by CytRx, a CytRx Affiliate or CytRx Sublicensee to comply with a timetable or
action set out in a report under Clause 6.2 shall not of itself be deemed to be a failure to
employ Reasonable Commercial Efforts.
	 
	6.4	 	ICIL’s receipt of any report under Clause 6.2 shall not be taken to waive or qualify the
Licensee’s obligations under Clause 6.1

	7	 	Improvements to the Licensed Patents.
	 
	7.1	 	Both Severable Improvements and Non-Severable Improvements made by CytRx and any Patent
Rights therein (“CytRx Foreground Improvements”) will be owned by CytRx. CytRx shall have
responsibility for filing any Patent Rights relating to CytRx Foreground Improvements and
shall own any subsequent patents. Except as set forth in Clause 7.2, Imperial and ICIL shall
have no rights in CytRx Foreground Improvements or

 

 

	 	 	be entitled to any additional payments with respect to CytRx’s exploitation of the CytRx
Foreground Improvements.
	 
	7.2	 	CytRx will notify ICIL of all Non-Commercially Sensitive CytRx Foreground Improvements which
are limited to Non-Severable Improvements (after CytRx has taken all steps it believes
necessary to protect such Improvements). Upon such notification CytRx will grant to Imperial a
royalty-free non-exclusive, non-sublicensable, world-wide licence to use such Non-Severable
Improvements solely for the purpose of teaching and scientific research for non-commercial
purposes.
	 
	7.3	 	Both Severable Improvements and Non-Severable Improvements made by Imperial and any Patent
Rights therein (“IC Foreground Improvements”) will be owned by ICIL. Imperial’s obligations
set out in Clause 2.3 in relation to the publication of its results shall apply to all IC
Foreground Improvements arising from the Research Group.
	 
	7.4	 	For 24 months after the date of this Agreement, ICIL and/or Imperial shall notify CytRx of
all Severable and Non-Severable Improvements arising from the Research Group promptly after
they are created, the date that such notification is received by CytRx being the “Notification
Date”.
	 
	7.5	 	If under Clause 7.4 ICIL notifies CytRx of the creation of a Non-Severable Improvement made
by Imperial it shall also state in such notice whether or not it intends to patent such
Non-Severable Improvement. CytRx shall within forty five (45) days of the Notification Date
inform ICIL whether it wishes to takes a licence of such Non-Severable Improvement.
	 
	7.6	 	If CytRx does not reply within such forty five (45) day period or states that it does not
wish to take a licence of the Non-Severable Improvement then ICIL shall be free to Exploit,
license or assign such Non-Severable Improvement as it sees fit.
	 
	7.7	 	If CytRx notifies ICIL in accordance with Clause 7.5 that it wishes to take a licence of such
Non-Severable Improvement and ICIL has indicated that it intends to file a patent on such
Non-Severable Improvement then ICIL will be entitled to control in its sole discretion the
prosecution of any Patent Rights relating to such Non-Severable

 

 

	 	 	Improvement, and such control shall include, but not be limited to, deciding which patent
attorney shall have the conduct of the prosecution, what claims to prosecute and the terms
of such claims, which countries in which to file for Patent Rights, the conduct of any
defence to an opposition (if any) and whether to appeal any decision. Such Patent Rights
will become part of the Licensed Patents and will be automatically licensed to CytRx under
Clause 2.1.1 of this Agreement provided that such licence will be limited to the Field.
ICIL and CytRx will decide what proportion of the patenting costs associated with the
prosecution of such Patent Rights will be paid by either Party, which will be dependant on
factors such as the scope of the claims and their relationship to the subject matter of this
Agreement and the benefit that each Party is likely to obtain from such patent protection.
In default of agreement the dispute will be subject to the dispute resolution procedure in
Clause 11.
	 
	7.8	 	If CytRx notifies ICIL in accordance with Clause 7.5 that it wishes to take a licence of such
Non-Severable Improvement and ICIL has indicated that it does not intend to file a patent on
such Non-Severable Improvement and CytrX believes that the Non-Severable Improvement should be
patented then:

	 	7.8.1	 	ICIL shall file for Patent Rights in relation to such Non-Severable
Improvement and shall own all subsequent Patents Rights; and
	 
	 	7.8.2	 	the length of time that publication is delayed under Clause 2.3 in relation to
any such Improvement shall be extended by thirty (30) Business Days to a total of sixty
(60) Business Days.

	7.9	 	CytRx will be entitled to control in its sole discretion the prosecution of any Patent Rights
filed under Clause 7.8.1, and such control shall include, but not be limited to, deciding
which patent attorney shall have the conduct of the prosecution, what claims to prosecute and
the terms of such claims, which countries in which to file for Patent Rights, the conduct of
any defence to an opposition (if any) and whether to appeal any decision. If ICIL file and
prosecute the Patent Rights then CytRx will within 30 days or receipt of an invoice from ICIL,
pay the patenting costs associated with the filing and prosecution

 

 

	 	 	of such Patent Rights and such Patent Rights will become part of the Licensed Patents and
will be automatically licensed to CytRx under Clause 2.1.1 of this Agreement.
	 
	7.10	 	If CytRx notifies ICIL in accordance with Clause 7.5 that it wishes to take a licence of such
Non-Severable Improvement and neither ICIL nor CytRx wishes to patent such Non-Severable
Improvement then it will be automatically licensed to CytRx (a) to the extent that it falls
within the scope of a Valid Claim of the Licensed Patents under Clause 2.1.1 of this Agreement
in addition to the Licensed Patents, and to extent that it does not falls within the scope of
a Valid Claim of the Licensed Patents under clauses 2.1.2 or 2.1.3 as appropriate depending on
the nature of the Improvement.
	 
	7.11	 	ICIL grants CytRx a first right to be granted a worldwide, exclusive licence to commercialise
any Severable Improvements in the Field to the Licensed Patents made by Imperial and notified
to CytRx under Clause 7.4, where such Severable Improvements are unencumbered by any rights of
any Third Party. In relation to any Severable Improvement CytRx shall notify ICIL within sixty
(60) Business Days of the Notification Date for that Severable Improvement (the “Decision
Period”) whether or not it wishes to take a licence of such Severable Improvement. If CytRx
notifies ICIL that it does wish to take a licence then the parties will negotiate in good
faith to agree terms. If:

	 	7.11.1	 	CytRx notifies ICIL that it does not wish to take a licence of such Severable
Improvement; or
	 
	 	7.11.2	 	CytRx does not notify ICIL within the Decision Period; or
	 
	 	7.11.3	 	the Parties cannot agree the terms of a licence to such Severable Improvement within
six (6) months of the end of the Decision Period (the “Negotiation Period”)

then ICIL will be free, subject to Clause 7.12, to license or assign the Severable
Improvement to a Third Party.

	7.12	 	If a Third Party makes a genuine offer to take a licence or an assignment of a Severable
Improvement that ICIL is free to license or assign under Clause 7.11 (a “Third Party

 

 

	 	 	Offer”) (in circumstances where CytRx and ICIL have
previously failed to agree terms under 7.11.3) within
a period of twenty four (24) months from the end of
the Negotiation Period then ICIL will notify CytRx
immediately and CytRx will have the option to match
the Third Party Offer within forty-five (45) days of
being so notified. If CytRx does match the offer then
it shall be granted a licence or assignment of the
Severable Improvement provided that it executes a
licence or assignment agreement within forty-five (45)
days (or such longer period agreed by the Parties) of
being notified by ICIL of the Third Party Offer. The
Parties will use reasonable endeavours to agree and
execute the licence or assignment agreement within the
three (3) month period. If the Parties do not execute
a licence or assignment agreement in respect of the
Severable Improvement within the three (3) month
period then ICIL will be free to license or assign the
Severable Improvement to a Third Party without any
further reference to CytRx.

	8	 	Improvements to the Materials
	 
	8.1	 	If the Research Group at Imperial creates an Improvement to the Biological Materials within
24 months of the date of this Agreement then such Improvement will be owned by ICIL and become
part of the Biological Materials. It will be exclusively licensed to CytRx for the Field under
the terms of Clause 2.1.2 of this Agreement and Imperial will supply CytRx with a reasonable
quantity of such Biological Materials within a reasonable time of notification of the
Improvement under Clause 7.4.
	 
	8.2	 	If the Research Group at Imperial creates an Improvement to the Related Technology within 24
months of the date of this Agreement then such Improvement will become part of the Related
Technology and will be non-exclusively licensed to CytRx for the Field under the terms of
Clause 2.1.3 of this Agreement.
	 
	8.3	 	Any Improvement made by CytRx to the Materials and any Patent Rights therein (“CytRx
Materials Improvements”) will be owned by CytRx. CytRx shall have responsibility for filing
any Patent Rights relating to CytRx Materials Improvements and shall own any subsequent
patents.

 

 

	 
	9	 	Prosecution of the Patents
	 
	9.1	 	Subject to Clause 9.3, CytRx will control in its sole discretion the prosecution of any
Patent Rights included within the Licensed Patents. Such control shall include, but not be
limited to, deciding which patent attorney shall have the conduct of the prosecution, what
claims to prosecute and the terms of such claims, the conduct of any defence to an opposition
(if any) and whether to appeal any decision.
	 
	9.2	 	Subject to Clause 9.4, CytRx shall only be obliged to prosecute the Licensed Patents within
the Patenting Territories but it may at its sole discretion prosecute the Licensed Patents
outside such territories. CytRx and its Affiliates and Sublicensees shall not conduct
screening activities relating to the identification of Licensed Products or Diagnostic
Products outside of the Patenting Territories.
	 
	9.3	 	CytRx will not narrow any claims, or abandon any patent applications within the Licensed
Patents in any Patenting Territory without the consent of ICIL, such consent not to be
unreasonably withheld or delayed.
	 
	9.4	 	If CytRx does not wish to apply for, maintain or register Patent Rights in connection with
the Licensed Patents in one or more of the Patenting Territories then ICIL shall not
unreasonably withhold its consent to the removal of such country from the list of Patenting
Territories. ICIL shall have the right to file, maintain or register patent applications at
its own expense in such country so removed, and such applications and resultant patents shall
not be subject to this Agreement.
	 
	9.5	 	CytRx will pay for all ongoing and future patent expenses in relation to the Licensed Patents
prosecuted under Clause 9.1 incurred from the Commencement Date until termination or expiry of
the Agreement and will instruct and settle all costs directly with the relevant patent agents
or other bodies requiring payment for patent expenses or maintenance fees as authorized by a
letter of instruction from ICIL.
	 
	9.6	 	CytRx shall be entitled to register this licence, if possible in abbreviated form, in
whichever territories it wishes. Imperial and ICIL shall provide all reasonable assistance to
CytRx to:

	 	9.6.1	 	register this Agreement throughout the world; and

 

 

	 	9.6.2	 	prosecute any Patent Rights within the Licensed Patents

including, without limitation, providing scientific support and advice, providing laboratory
notebooks and signing further documentation and handing over any current files relating to
the prosecution of the Licensed Patents. CytRx will meet Imperial’s and ICIL’s reasonable
out of pocket external legal costs and travel expenses incurred in providing such
assistance.

	10	 	Proceedings relating to the Licensed Patents
	 
	10.1	 	Each Party shall notify the other promptly during the term of the Agreement if it becomes
aware of:

	 	10.1.1	 	any proceedings or applications emanating from a Third Party challenging the validity
or enforceability of the Licensed Patents including, without limitation, any
revocation, interference or opposition proceedings; or
	 
	 	10.1.2	 	a Third Party taking or threatening to take any proceedings for infringement of any
patents of that Third Party by reason of CytRx’s or CytRx Sublicensees’ operation of
the Licensed Patents or the manufacture, use or sale of Licensed Products; or
	 
	 	10.1.3	 	any patent infringement or potential patent infringemnt of the Licensed Patents by a
Third Party (all such proceedings in Clauses 10.1.1 to 10.1.3 being “Actions”).

	10.2	 	CytRx shall have the first right at its sole discretion and cost to conduct (or have a CytRx
Sublicensee conduct) any lawsuits, claims or proceedings relating to any Actions. ICIL and
Imperial shall provide CytRx (or the CytRx Sublicensee) with all reasonable assistance in
relation to any such lawsuits, claims or proceedings and shall, if necessary, consent to be
joined as a party to them.
	 
	10.3	 	If CytRx (or the CytRx Sublicensee) does not bring or defend any Action within ninety (90)
days of the date that such Action is first notified by one Party to both of the other Parties
then ICIL can bring or defend such Action and CytRx and Imperial shall provide

 

 

	 	 	reasonable assistance to ICIL at ICIL’s cost. ICIL can require CytRx to grant a sublicence
under this Agreement to any infringer that is the subject of an Action brought by ICIL under
this Clause 10.3, provided that the terms of such sub-licence are reasonably acceptable to
CytRx and Imperial.
	 
	10.4	 	IfCytRx brings proceedings against a Third Party for infringement of the Licensed Patents, or
any of them, and ICIL is joined in as a party to such proceedings then ICIL will have the
option to pay two percent (2%) of the legal costs associated with such proceedings including
two percent (2%) of any costs awarded against the Parties. If ICIL exercises this option then
it will share any damages awarded (after all patenting costs incurred in relation to the
Licensed Patents at the point that the damages are awarded have been deducted from such
damages and paid to the Party who incurred such patenting costs) in the proportion ninety
eight percent (98%) to CytRx and two percent (2%) to ICIL. If CytRx pays all the legal costs
it shall retain all the damages awarded.
	 
	10.5	 	If ICIL brings proceedings against a Third Party for infringement of the Licensed Patents, or
any of them, and CytRx is joined in as a party to such proceedings then CytRx will have the
option to pay half the legal costs associated with such proceedings including half of any
costs awarded against the Parties. If CytRx exercises this option then it will share any
damages awarded (after all patenting costs incurred in relation to the Licensed Patents at the
point that the damages are awarded have been deducted from such damages and paid to CytRx) in
the proportion fifty per cent (50%) to CytRx and fifty percent (50%) to ICIL. If ICIL pays all
the legal costs it shall retain all the damages awarded.
	 
	11	 	Dispute Resolution Procedure
	 
	11.1	 	The Parties will use all reasonable endeavours to resolve disputes arising out of this
Agreement. The Parties may refer any dispute to the CEO of CytRx and Managing Director of
ICIL, who shall co-operate in good faith to resolve the dispute as amicably as possible within
15 Business Days of the dispute being referred to them.
	 
	11.2	 	If the CEO of CytRx and Managing Director of ICIL fail to resolve the dispute in the allotted
time, the Parties may within that period on the written request of both Parties

 

 

	 	 	agree in writing to enter into an alternative dispute resolution procedure with the
assistance of a mediator agreed by the parties or, in default of such agreement appointed by
the Centre for Dispute Resolution, Harbour Exchange Square, London.
	 
	11.3	 	If the alternative dispute procedure fails to resolve the dispute then the dispute will be
resolved by arbitration in accordance with Clause 26.
	 
	12	 	Representations and Warranties
	 
	12.1	 	Each Party represents, warrants, undertakes and agrees for the benefit of the other that:

	 	12.1.1	 	it has full power to enter into and perform this Agreement;
	 
	 	12.1.2	 	so far as it is aware the execution and delivery of this Agreement and the
performance of and compliance with its terms and provisions will not:

	 	(i)	 	conflict with or result in a breach of, or constitute a default
under, any agreement or instrument to which it is a party or by which it is
bound or with its memorandum and articles of association or certificate of
incorporation; or
	 
	 	(ii)	 	conflict with or result in a breach of any law, regulation or
order of any court.

	12.2	 	ICIL represents, warrants, undertakes and agrees that:

	 	12.2.1	 	full and accurate details of all registrations of and applications for registration
of the Licensed Patents as at the Commencement Date are set out Schedule 1;
	 
	 	12.2.2	 	to the best of its actual knowledge (and without having made any special enquiries)
it is the sole legal and beneficial owner of the Licensed Patents and Materials;
	 
	 	12.2.3	 	to the best of its actual knowledge (and without having made any special enquiries)
it does not know of any reason why the Patent Application will not be

 

 

	 	 	 	granted at least in part and with commercially significant claims or any Patent
Rights based on it will not be granted in any country;
	 
	 	12.2.4	 	to the best of its actual knowledge (and without having made any special enquiries)
it does not know of any activities carried out now by any Third Party which if carried
out after any of the Licensed Patents are granted would infringe such Licensed Patents;
	 
	 	12.2.5	 	to the best of its knowledge (and without having made any special enquiries) it does
not own nor is it licensed to use any intellectual property that relates to RIP140 in
the area of obesity or diabetes other than the Licensed Patents;
	 
	 	12.2.6	 	to the best of its knowledge (and without having made any special enquiries) it does
not own nor is it licensed to use any intellectual property that:

	 	(a)	 	would prevent CytRx Exploiting the rights granted under this
Agreement; or
	 
	 	(b)	 	would result in CytRx being liable to pay a royalty or any
other sum, in addition to the sums set out in Clause 4 above, to Exploit the
Licensed Patents or Materials; or

	 	12.2.7	 	to the best of its actual knowledge and without having conducted any special
enquiries, all necessary registration, maintenance and renewal fees currently due in
connection with the Licensed Patents have been made and all necessary documents and
certificates in connection with such Licensed Patents have been filed with the relevant
patent or other authorities in the United Kingdom for the purposes of maintaining such
Licensed Patents;

	12.3	 	Imperial represents, warrants, undertakes and agrees that it will use its best endeavours to
ensure that any Biological Materials supplied to CytRx under this Agreement are in accordance
with the description of such Biological Materials. If they are found by CytRx not be in
accordance with such description then, without prejudice to any other rights accrued by CytRx
as a result of the breach of Imperials obligation in this Clause 12.3,

 

 

	 	 	Imperial will use its best endeavours to provide Biological Materials in accordance with the
description.
	 
	12.4	 	Without limiting the scope of Clause 12.2 and 12.3, ICIL does not give any warranty,
representation or undertaking:

	 	12.4.1	 	as to the efficacy, scope or usefulness of the Licensed Patents or Materials; or
	 
	 	12.4.2	 	except as expressly set forth in clause 12.2.6 that the use of any of the Licensed
Patents or Related Technology, the manufacture, sale or use of the Licensed Products or
the exercise of any of the rights granted under this Agreement after the date of this
Agreement will not infringe any other intellectual property or other rights of any
other person; or
	 
	 	12.4.3	 	that the Licensed Patents or Materials or any other information communicated by ICIL
to CytRx under or in connection with this Agreement will produce Licensed Products of
satisfactory quality or fit for the purpose for which CytRx intended; or
	 
	 	12.4.4	 	subject to Clause 10.2, as imposing any obligation on ICIL to bring or prosecute
actions or proceedings against third parties for infringement or to defend any action
or proceedings for revocation of any of the Licensed Patents; or
	 
	 	12.4.5	 	as imposing any liability on ICIL in the event that any third party supplies Licensed
Products to end-user customers.

	12.5	 	CytRx acknowledges that the Materials and Related Technology are at an early stage of
development. Accordingly, but subject to Clause 12.3, specific results cannot be guaranteed
and any results, materials, information or other items (together “Delivered Items”) provided
under this Agreement are provided “as is” and without any express or implied warranties,
representations or undertakings other than that the Delivered Items have been created and
provided in good faith. As examples, but without limiting the foregoing, ICIL does not give
any warranty that Delivered Items are of merchantable or

 

 

	 	 	satisfactory quality, are fit for any particular purpose, or are viable, uncontaminated,
safe or non-toxic.
	 
	12.6	 	Except as expressly stated in this Clause 12, no representations, or warranty whatsoever are
made or given by or on behalf of the Parties.
	 
	12.7	 	Subject always to the provisions of Clause 12.11, CytRx shall indemnify ICIL and Imperial
against any loss, damages, costs, expenses or other liabilities which are awarded against or
incurred by ICIL and Imperial as a result of any claim or threatened claim against them by a
Third Party concerning the use by CytRx, its Affiliates or any of its sub-licensees of the
Licensed Patents or Materials or otherwise in connection with the manufacture, use or sale of
or any other dealing in any of the Licensed Products by CytRx or its Affiliates or any of its
sub-licensees (hereinafter a “Claim”), provided:

	 	12.7.1	 	CytRx shall not be obligated to indemnify ICIL and/or Imperial under this Clause if
it is shown by evidence acceptable in a court of law having jurisdiction over the
subject matter and meeting the appropriate degree of proof for such action, that the
Claim was the result of the negligence, failure to reasonably act or wilful misconduct
of any employee or agent of ICIL and/or Imperial or the conduct of any activity to be
performed by ICIL and/or Imperial pursuant to this Agreement; and
	 
	 	12.7.2	 	CytRx shall have no obligation under this Clause 12.7 unless ICIL and/or Imperial:

	 	(a)	 	gives CytRx prompt written notice of any Claim for which it
seeks to be indemnified under this Agreement;
	 
	 	(b)	 	CytRx is granted full authority and control over the defence
(at the cost of CytRx), including settlement, against such Claim; and
	 
	 	(c)	 	ICIL and/or Imperial co-operates as reasonably required with
CytRx and its agents in defence of such Claim at the cost of CytRx.

 

 

	12.8	 	Imperial and/or ICIL shall have the right to participate in the defence of any such Claim
referred to in Clause 12.7 utilising attorneys of its choice at its own cost and expense,
provided, however, that CytRx shall have full authority and control to handle any such Claim,
including any settlement or other disposition thereof, for which the ICIL and/or Imperial
seeks indemnification under Clause 12.7.
	 
	12.9	 	CytRx undertakes to make no claim against any employee, student, agent or appointee of ICIL
or Imperial, being a claim which seeks to enforce against any of them any liability whatsoever
in connection with this Agreement or its subject matter save that CytRx can apply for
injunctive relief in relation to an employee, student, agent or appointee of ICIL or Imperial
if they have (or are threatening to) wilfully disclose any Confidential Information under this
Agreement.
	 
	12.10	 	In any event, the maximum liability of ICIL to CytRx under or otherwise in connection with
this Agreement or its subject-matter shall not exceed the return of all monies paid by CytRx
under this Agreement, together with interest on the balance of such monies from time to time
outstanding, accruing from day to day at the National Westminster Bank plc base rate from time
to time in force.
	 
	12.11	 	Notwithstanding any other provision of this Agreement, no Party shall be liable to any other
Party to this Agreement in contract, tort, negligence, breach of statutory duty or otherwise
for any loss, damage, costs or expenses of any nature whatsoever incurred or suffered by that
other party or its Affiliates of an indirect or consequential nature including without
limitation any economic loss or other loss of turnover, profits, business or goodwill.

	13	 	Confidentiality 
	 
	13.1	 	The Parties each undertake and agree to:

	 	13.1.1	 	only use the Confidential Information for the purposes envisaged under this Agreement
and not to use the same for any other purpose whatsoever;

 

 

	 	13.1.2	 	ensure that only those of its officers and employees who are directly concerned with
the carrying out of this Agreement have access to the Confidential Information on a
strictly applied “need to know” basis and are informed of the secret and confidential
nature of it;
	 
	 	13.1.3	 	keep the Confidential Information secret and confidential and not to directly or
indirectly disclose or permit to be disclosed the same to any Third Party excluding any
consultants or other advisors for any reason without the prior written consent of the
Disclosing Party;

	13.2	 	Subject to clause 24, the Parties each agree not to disclose any of the terms of this
Agreement or its existence to any Third Party without the prior consent of the other Party,
except as may be required by law or to fulfil any other obligations under this Agreement.
	 
	13.3	 	The obligations of confidence referred to in Clause 13.1 shall not extend to any Confidential
Information which:

	 	13.3.1	 	is or becomes generally available to the public otherwise than by reason of breach by
a Recipient Party of the provisions of this Clause;
	 
	 	13.3.2	 	is known to the Recipient Party and is at its free disposal (having been generated
independently by the Recipient Party or a Third Party in circumstances where it has not
been derived directly or indirectly from the Disclosing Party’s Confidential
Information prior to its receipt from the Disclosing Party provided that evidence of
such knowledge is furnished by the Recipient Party to the Disclosing Party within 28
days of receipt of that Confidential Information);
	 
	 	13.3.3	 	is subsequently disclosed to the Recipient Party without obligations of confidence by
a Third Party owing no such obligations to the Disclosing Party in respect of that
Confidential Information; or
	 
	 	13.3.4	 	is required by law to be disclosed (including as part of any regulatory submission or
approval process) and then only when prompt written notice of this requirement has been
given to the Disclosing Party so that it may, if so advised,

 

 

	 	 	 	seek appropriate relief to prevent such disclosure provided always that in such
circumstances such disclosure shall be only to the extent so required and shall be
subject to prior consultation with the Disclosing Party with a view to agreeing
timing and content of such disclosure.

	13.4	 	All Confidential Information disclosed by one Party to the other shall remain the property of
the Disclosing Party. In the event that a court or Competent Authority assumes partial or
complete control over the assets of a Recipient Party based on the insolvency or bankruptcy of
that Party, the Recipient Party shall:

	 	13.4.1	 	promptly notify such court or Competent Authority:
	 
	 	(a)	 	that Confidential Information received from the Disclosing Party under this
Agreement remains the property of the Disclosing Party; and
	 
	 	(b)	 	of the confidentiality obligations under this Agreement; and
	 
	 	13.4.2	 	to the extent permitted by law, take all steps necessary or desirable to maintain the
confidentiality and security of the Disclosing Party’s Confidential Information and to
ensure that the court or Competent Authority maintains that Confidential Information in
confidence in accordance with this Agreement.

	13.5	 	The obligations of the Parties under Clause 13.1 to 13.4 shall survive the expiration or
termination of this Agreement for whatever reason for a period of 7 years.
	 
	13.6	 	The Parties understand and agree that remedies in damages may be inadequate to protect
against any breach of any of the provisions of this Clause 13 by either Party or their
employees, officers or any other person acting in concert with it or on its behalf.
Accordingly, each Party shall be entitled to seek the granting of interim and final injunctive
relief by a court of competent jurisdiction in the discretion of that court against any action
that constitutes any breach of this Clause without the necessity of posting a bond or proving
damages.

 

 

	 
	14	 	Duration and Termination 
	 
	14.1	 	The term of this Agreement shall extend to the expiry of the last Valid Claim in any country
or the earlier termination of this Agreement in accordance with Clauses 14.2 or 14.3 below.
	 
	14.2	 	CytRx shall have the right to terminate this Agreement upon three (3) months written notice.
	 
	14.3	 	CytRx shall have the right to terminate the Agreement and the Licence forthwith in the event
that:

	 	(a)	 	ICIL or Imperial commit a material or persistent breach of any of their
material obligations under this Agreement which is incapable of remedy; or
	 
	 	(b)	 	ICIL or Imperial fail to remedy, where it is capable of remedy, or persists in
any breach of any of their obligations under this Agreement after having been required
in writing to remedy or desist from such breach within a period of sixty (60) days of
receipt of a notice from CytRx detailing such breach and of its intention to exercise
its rights under this Clause.

	14.4	 	ICIL shall have the right to terminate the Agreement and the Licence forthwith in the event
that:

	 	(a)	 	CytRx commits a material or persistent breach of any of its material
obligations under this Agreement which is incapable of remedy; or
	 
	 	(b)	 	CytRx fails to remedy, where it is capable of remedy, or persists in any
material breach of any of its obligations under this Agreement after having been
required in writing to remedy or desist from such breach within a period of sixty (60)
days of receipt of a notice from ICIL detailing such breach and of its intention to
exercise its rights under this Clause.

	14.5	 	Upon termination or expiry of this Agreement for any reason whatsoever:

	 	14.5.1	 	the relationship of the Parties hereunder shall cease save as (and to the extent)
expressly provided for in this Clause 14.5;

 

 

	 	14.5.2	 	ICIL shall grant licences to each CytRx Sublicensee on the equivalent terms as those
set out in this Agreement which will allow such CytRx Sublicensee to continue to
Exploit or use the rights granted to it by CytRx under this Agreement (with no
obligation for CytRx to make payments to ICIL based on sales of Licensed Products by
the CytRx Sublicensee), provided always that the termination of this Agreement was not
caused directly or indirectly by a CytRx Sublicensee in which case ICIL shall have no
obligation under this Clause 14.5.2 with respect to such CytRx Sublicensee;
	 
	 	14.5.3	 	CytRx and any CytRx Sublicensee shall be entitled to fulfill any orders which, as at
the date of termination, they are contracted to fulfill and otherwise sell or dispose
of any stock which is in their possession, custody or control at the date of
termination provided that CytRx shall pay royalties on such sales on the terms of this
Agreement. Within six (6) months of the date of expiry or termination of this
Agreement, CytRx will return to ICIL or dispose of all Materials or Related Technology
in its possession and cease to Exploit Licensed Products which incorporate Biological
Materials that have been provided to CytRx under this Agreement by ICIL or Imperial,
provided that, following termination of this Agreement by CytRx, CytRx may continue to
Exploit Licensed Products subject to CytRx continuing to comply with the provisions of
Clauses 4 and 5 relating to the payment of milestones and royalties and Clauses 12.7 to
12.11. If following termination of this Agreement CytRx does so continue to Exploit
Licensed Products in any country where there is no Valid Claim still in force the
royalty payable pursuant to Clause 4 on Licensed Products sold in that country will be
reduced by fifty (50) per cent;
	 
	 	14.5.4	 	CytRx shall have no obligation to prosecute, maintain or enforce the Licensed Patents
and any patented Non-Severable Improvements and shall transfer to ICIL all right and
title to the Licensed Patents, any patented Non-Severable Improvements and intellectual
property rights in any Related Technologies; and

 

 

	 	14.5.5	 	Any overpayments made by CytRx to ICIL, that have not been credited against royalties
or other amounts payable by CytRx to ICIL under Clause 5.8 will become immediately due
and payable by ICIL to CytRx.

	14.6	 	The obligation to make payments under this Agreement with respect to any period prior to its
expiry or termination shall survive the expiry or termination of this Agreement.
	 
	14.7	 	Termination of this Agreement for whatever reason shall not affect the accrued rights of the
Parties arising in any way out of this Agreement as at the date of termination including
without limitation the right to recover damages against each other and all provisions which
are expressed or are implied to survive this Agreement shall remain in full force and effect.
	 
	15	 	Commercialisation Option
	 
	15.1	 	Following termination of this Agreement, if CytRx notifies in writing ICIL (an “Option
Notice”) that it no longer wishes to develop and/or market a Licensed Product for the
treatment of obesity (an “Option Product”) ICIL will have a first right to take over the
development of such an Option Product and to purchase from CytRx at a commercially reasonable
rate all information, data, intellectual property, Know-How, regulatory approval data,
marketing authorisations relating to it.
	 
	15.2	 	If ICIL notifies CytRx in writing within thirty (30) days of the Option Notice that it wishes
to enter into negotiations to take over the development of such an Option Product and to
purchase the rights set out in Clause 15.1, then the Parties will promptly enter into
negotiations to agree terms.
	 
	15.3	 	The value of the Option Product will be based on:

	 	15.3.1	 	the direct costs incurred by CytRx in developing the product up to the date of any
agreement between CytRx and ICIL to transfer the development of such a Licensed Product
and to purchase the rights set out in Clause 15.1; and

 

 

	 	15.3.2	 	a premium to take account of the risk taken by CytRx in developing the Option
Product up to that point, the likelihood of the product reaching the market and its
potential sales. The valuation of the Option Product shall be carried out by the
Parties according to reasonable and mutually agreed principles at the time that ICIL
notifies CytRx that it wishes to enter into negotiations.

	15.4	 	If the negotiations described in Clause 15.2 do not result in an executed agreement within
seven (7) months of the date of the Option Notice then CytRx will be free to negotiate with a
Third Party and dispose to them the Option Product and all information, data, intellectual
property, Know-How, regulatory approval data, marketing authorisations relating to it.
	 
	15.5	 	If ICIL notifies CytRx in writing within thirty (30) days of the Option Notice that it does
not wish to enter into negotiations, or does not respond within such thirty (30) day period,
then CytRx will be free to negotiate with a Third Party and dispose to them the Option Product
and all information, data, intellectual property, Know-How, regulatory approval data,
marketing authorisations relating to it.

	16	 	Assignment
	 
	16.1	 	This Agreement may not be assigned by either Party without the prior written consent of the
other Party (such consent not to be unreasonably withheld and such consent or refusal of
consent to be given within 30 days of a request), except that either Party may assign the
Agreement to any of its Affiliates or to a successor in connection with the merger,
consolidation, or sale of all or substantially all of its assets or that portion of its
business pertaining to the subject matter of the Agreement, with prompt notice to the other
party of any such assignment. The Agreement shall inure to the benefit of and be binding upon
the Parties and their respective lawful successors and assigns.
	 
	17	 	Force Majeure
	 
	17.1	 	If a Party (the “Non-Performing Party”) is unable to carry out any of its obligations under
this Agreement due to Force Majeure this Agreement shall remain in effect but the Affected
Party’s relevant obligations under this Agreement and the corresponding

 

 

	 	 	obligations of the other Party
under this Agreement, shall be
suspended for a period equal to
the circumstance of Force
Majeure.
	 
	18	 	Waiver
	 
	18.1	 	Save as expressly provided in this Agreement neither Party shall be deemed to have waived any
of its rights or remedies whatsoever provided by law or under this Agreement unless the waiver
is made in writing, signed by a duly authorised representative of that Party and may be given
subject to any conditions thought fit by the grantor. Unless otherwise expressly stated any
waiver shall be effective only in the instance and for the purpose for which it is given.
	 
	18.2	 	No delay or failure of any Party in exercising or enforcing any of its rights or remedies
whatsoever shall operate as a waiver of those rights or remedies or so as to preclude or
impair the exercise or enforcement of those rights or remedies. No single or partial exercise
or enforcement of any right or remedy by any Party shall preclude or impair any other exercise
or enforcement of that right or remedy by that Party.
	 
	19	 	Severance of Terms
	 
	19.1	 	If the whole or any part of this Agreement (including any one or more of the clauses of this
Agreement or any sub-clause or paragraph or any part of one or more of these clauses) is or
becomes or is declared illegal, invalid or unenforceable in any applicable jurisdiction for
any reason (including both by reason of the provisions of any legislation and also by reason
of any decision of any court or Competent Authority which either has jurisdiction over this
Agreement or has jurisdiction over any of the Parties) then:

	 	19.1.1	 	in the case of the illegality, invalidity or un-enforceability of the whole of this
Agreement it shall terminate in relation to the jurisdiction in question; or
	 
	 	19.1.2	 	in the case of the illegality, invalidity or un-enforceability of part of this
Agreement that part shall be severed from this Agreement in the jurisdiction in
question and that illegality, invalidity or un-enforceability shall not in any way

 

 

	 	 	 	whatsoever prejudice or affect the remaining parts of this Agreement which shall
continue in full force and effect.

	20	 	Entire Agreement/Variations
	 
	20.1	 	This Agreement constitutes the entire agreement and understanding between the Parties and
supersedes all prior oral or written understandings, arrangements, representations or
agreements between them relating to the subject matter of this Agreement. The Parties
acknowledge that no claims shall arise in respect of any understandings, arrangements,
representations or agreements so superseded. No director, employee or agent of any Party is
authorised to make any representation or warranty to another Party not contained in this
Agreement, and each Party acknowledges that it has not relied on any such oral or written
representations or warranties. Nothing in this Agreement removes or overrides any right of
action by any Party in respect of any fraudulent misrepresentation, fraudulent concealment or
other fraudulent action.
	 
	20.2	 	No variation, amendments, modification or supplement to this Agreement shall be valid unless
made in writing in the English language and signed by a duly authorised representative or
representatives of each Party.
	 
	21	 	Notices
	 
	21.1	 	Any notice or other communication to be given pursuant to or made under or in connection with
the matters contemplated by this Agreement shall be in writing in the English language and
shall be delivered by courier, sent by post or sent by facsimile to the address or facsimile
number of the recipient set out in Schedule 4 or as specified by the recipient from time to
time in accordance with this Clause 21. Notices sent by e-mail shall not be valid of
themselves and must be confirmed in hard copy form by courier, by post or facsimile.
	 
	21.2	 	Any notice given pursuant to this Clause 21 shall be deemed to have been received:

	 	21.2.1	 	in the case of delivery by hand, when delivered; or

 

 

	 	21.2.2	 	in the case of sending by post:

	 	(a)	 	where posted in the country of the addressee, on the second working day
following the day of posting, and
	 
	 	(b)	 	where posted in any other country, on the fifth working day following the day
of posting; or
	 
	 	21.2.3	 	in the case of facsimile, on acknowledgement by the recipient’s facsimile receiving
equipment on a Business Day if the acknowledgement occurs before 1700 hours local time
of the recipient and in any other case on the following Business Day.

	22	 	Counterparts
	 
	22.1	 	This Agreement may be executed in any number of counterparts and by the different Parties on
separate counterparts, each of which when so executed shall be an original of this Agreement,
and all of which shall together constitute one and the same instrument. Complete sets of
counterparts shall be lodged with each Party.
	 
	23	 	This Agreement not to constitute a Partnership; Third Parties.
	 
	23.1	 	Nothing on this Agreement and no action taken by the Parties pursuant to this Agreement shall
constitute or be deemed to constitute a partnership association, joint-venture or other
co-operative entity between the Parties and none of the Parties shall have any authority to
bind the others in any way except as provided in this Agreement.
	 
	23.2	 	The Contracts (Rights of Third Parties) Act 1999 will not apply to this Agreement. No person
who is not a party to this Agreement (including any employee, officer, agent, representative
or subcontractor of either party) except any Affiliates of CytRx will have the right (whether
under the Contracts (Rights of Third Parties) Act 1999 or otherwise) to enforce any term of
this Agreement which expressly or by implication confers a benefit on that person without the
express prior agreement in writing of the Parties which agreement must refer to this Clause
23.2.

 

 

	24	 	Press Releases
	 
	24.1	 	Subject to Clause 24.2, no public announcement or other disclosure to Third Parties (except
to Affiliates of the Parties) concerning this Agreement shall be made, whether directly or
indirectly, by any Party to this Agreement without first obtaining the approval of the other
Party and agreement upon the nature and text of such announcement or disclosure with the
exception that:

	 	24.1.1	 	a Party may disclose the full terms of this Agreement to its investment bankers,
lawyers, accountants and other professional advisors without the other Party’s prior
approval provided that such disclosure is made under the terms of confidentiality
whether express or implied; and
	 
	 	24.1.2	 	a Party may disclose those terms which it is required by a Directive to disclose and
CytRx may file a copy of the Agreement with the United States Securities and Exchange
Commission provided that it takes advantage of all provisions to keep confidential as
many terms of the Agreement as possible.
	 
	 	24.1.3	 	a Party may further disclose the terms where such disclosure is a repeat of a
previous disclosure or items included in such previous disclosure..

	24.2	 	CytRx will use reasonable commercial endeavours to provide a draft press release to ICIL by
18 May 2004. Such press release will not be issued for publication until its contents have
been agreed by CytRx and ICIL. The Parties will use reasonable endeavours to agree the terms
of such press release within a reasonable time with a view to CytRx publishing the press
release on 19 or 20 May 2004.
	 
	25	 	Governing Law
	 
	25.1	 	The validity and construction and interpretation of this Agreement and any determination of
the performance which it requires shall be governed by the internal laws of the State of New
York, USA.

 

 

	 
	26	 	Jurisdiction
	 
	26.1	 	Subject to Clauses 11 and 26.2, all disputes between the Parties arising under, out of or
relating to this Agreement or arising out of the circumstances and relationships contemplated
by this Agreement including disputes relating to the validity, construction or interpretation
of this Agreement and including its formation, validity, binding effect, interpretation,
performance, breach or termination as well as non-contractual claims and including disputes
relating to pre-contractual representations which result in any action or proceeding shall be
referred to and finally resolved by arbitration under the Rules of the ICC International Court
of Arbitration which Rules are deemed to be incorporated by reference into this Clause. The
number of arbitrators shall be one. The place of arbitration shall be New York. The language
to be used in the arbitral proceedings shall be English.
	 
	26.2	 	Clauses 11 and 26.1 shall not prevent either Party applying for and obtaining interim relief
from a court.

IN WITNESS OF THE ABOVE the Parties have signed this Agreement on the date written at the head of
this Agreement.

	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	SIGNED by

	 	 	)	 	 	/s/ Susan Searle	 	 
	 

	 	 	 	 	 	 	 	 
	for and on behalf of

	 	 	)	 	 	Authorised Signatory	 	 
	IMPERIAL COLLEGE INNOVATIONS LIMITED

	 	 	)	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	SIGNED by

	 	 	)	 	 	/s/ Peter Bearman	 	 
	 

	 	 	 	 	 	 	 	 
	for and on behalf of

	 	 	)	 	 	Authorised Signatory	 	 
	IMPERIAL COLLEGE

	 	 	)	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	SIGNED for and on behalf of
	 	 	 	 	 	 	 	 
	CYTRX CORPORATION by

	 	 	)	 	 	/s/ Steven Kriegsman	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	)	 	 	Authorised Signatory	 	 

 

 

Schedule 1

Licensed Patents

PCT application PCT/2004/000413 filed on 3rd February 2004 and claiming priority
from UK priority patent application number 0302446.0 filed 3rd February 2003
entitled “Screening for Modulators of Fat Storage”

 

 

Schedule 2

Biological Materials

	 	•	 	Animals: RIP140 null mice – upon request 3 pairs of heterozygous males and females
	 
	 	•	 	Cells:   RIP140 null cells called RIPKO-1.
	 
	 	•	 	Rip140/ nuclear receptor responsive Reporter cell lines (e.g., PPRE-luciferase, ERE Luc,
SRE-Luc 
	 
	 	•	 	DNA clones: Expression vectors for RIP140 and mutant version thereof.
	 
	 	•	 	Expression vectors for RIP140 expressed as GST or other fusion protein  
	 
	 	•	 	Reporter assays & NR vectors
	 
	 	•	 	Antibodies: MP45 polyclonal antibody and 6D7 MAb.

 

 

Schedule 3

Expert’s Decision

	1.	 	Any matter or dispute relating to (a) the calculation method for royalty payments to be made
on any Combination Product or (b) the valuation of any Sublicensing Revenue received by CytRx
in a form other than cash shall be referred to a person suitably qualified to determine that
matter or dispute (an “Expert”) who shall be nominated jointly by the Parties or, failing
agreement between the Parties within twenty (20) Business Days of a written request by either
Party to the other seeking to initiate the Experts’ Decision procedure set out below, either
Party may request the president or chairman for the time being of The American Pharmaceutical
Manufacturers Association or any successor body to it to nominate the Expert.
	 
	2.	 	The Parties shall within fourteen (14) days of the appointment of the Expert meet with him or
her in order to agree a program for the exchange of any relevant information and the structure
to be adopted for the negotiations.
	 
	3.	 	In all cases the terms of appointment of the Expert by whomsoever appointed shall include:

	 	3.1.	 	a commitment by the Parties to share equally the payment of the Expert’s fee;
	 
	 	3.2.	 	a requirement on the Expert to act fairly as between the Parties and according
to the principles of natural justice;
	 
	 	3.3.	 	a requirement on the Expert to hold professional indemnity insurance both then
and for three (3) years following the date of his or her determination;
	 
	 	3.4.	 	a commitment by the Parties to supply to the Expert all such assistance,
documents and information as he or she may require for the purpose of his or her
determination; and
	 
	 	3.5.	 	a commitment by the Parties that all negotiations connected with the dispute
shall be conducted in confidence and without prejudice to the rights of the Parties in
any future proceedings.

	4.	 	The Expert’s recommendations shall be reduced to writing and once signed by their duly
authorised representatives, shall be binding on the Parties (save in the case of negligence or
manifest error on the part of the Expert).

 

 

 

	 	 	 	 
		 
	Schedule 4
		 
		 
	Addresses for Notices
		 
		 
		ICIL and Imperial:

	 	Imperial College Innovations
		 
		 

	 	Imperial College London
		 
		 

	 	12th Floor, EEE Building, South Kensington

Campus, London SW7 2AZ, UK
		 
		 

	 	Facsimile: (0207) 589 3553 or (0207) 594 6584
		 
		 

	 	Attention: Managing Director
		 
		 
		CytRx

	 	CytRx Corporation
		 
		 

	 	11726 San Vicente Boulevard,
		 
		 

	 	Suite 650,
		 
		 

	 	Los Angeles,
		 
		 

	 	California 90049 USA
		 
		 

	 	Facsimile: +310 826 5529
		 
		 

	 	Attention: Steven Kriegsman, CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]